1. Introduction
2. Recent discoveries on MAO
inhibitors
3. New targets of MAO inhibitors
4. New associations with other
drugs of classical MAO
inhibitors
5. New administration routes of
classical MAO inhibitors
6. New synthetic process of MAO
inhibitors
7. Expert opinion
Review
Focusing on new monoamineoxidase inhibitorsAdriana Bolasco†, Simone Carradori & Rossella FioravantiDipartimento di Chimica e Tecnologie del Farmaco, Universita degli Studi di Roma
“La Sapienza” , P.le Aldo Moro, 5 00185 Rome, Italy
Importance of the field: Monoamine oxidase (MAO) plays a significant role
in the control of intracellular concentration of monoaminergic neurotrans-
mitters or neuromodulators and dietary amines. The rapid degradation of
these molecules ensures the proper functioning of synaptic neurotransmission
and is critically important for the regulation of emotional and other brain
functions. Furthermore, modulators of neurotransmitters exert pleiotropic
effects on mental and cognitive functions. The by-products of MAO-mediated
reactions include several chemical species with neurotoxic potential. It is
widely speculated that prolonged or excessive activity of these enzymes
may be conducive to mitochondrial damages and neurodegenerative distur-
bances. In keeping with these premises, the development of human MAO
inhibitors has led to important breakthroughs in the therapy of several
neuropsychiatric disorders.
Areas covered in this review: This review highlights the recent MAO inhibi-
tors related patents published from July 2005 to December 2009. It also
reports on new associations of already known MAO inhibitors with other
drugs, innovative therapeutic targets, MAO inhibitors obtained by plants
extraction, alternative administration routes and synthetic processes.
What the reader will gain: The reader will gain an overview of the main
structures being investigated and their biological activities.
Take home message: Several of these MAO inhibitors appear promising for
further clinical development.
Keywords: Alzheimer’s disease, depression, MAO inhibitor, neuroprotection,
Parkinson’s disease
Expert Opin. Ther. Patents (2010) 20(7):909-939
1. Introduction
Monoamine oxidase (MAO) (EC 1.4.3.4) is an outer mitochondrial membrane-bound enzyme involved in the oxidative degradation of biogenic amines, such asneurotransmitters, and xenobiotic arylalkylamines to aldehydes, by using O2 asan electron acceptor. To complete the catalytic cycle, the reduced flavin adeninedinucleotide cofactor reacts with O2 to generate oxidized flavin and hydrogenperoxide (H2O2). All mammals contain both isoforms of MAO, namedMAO-A and MAO-B, which are localized in different tissues. Human MAO-A(hMAO-A) and human MAO-B (hMAO-B) are encoded by separate genes shar-ing a common intron/exon organization and are constituted by different amino-acid sequences that are ~ 70% identical. The A isoform preferentially metabolizesnorepinephrine (NA) and 5-HT and is inhibited by clorgyline, whereas theB isoform prefers benzylamine as substrate and is inhibited by (R)-deprenyl
10.1517/13543776.2010.495716 © 2010 Informa UK Ltd ISSN 1354-3776 909All rights reserved: reproduction in whole or in part not permitted
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
and rasagiline. Tyramine and dopamine are equally metab-olized by both forms of the enzyme [1,2]. Selective MAO-A inhibitors are used clinically as antidepressants and anxio-lytics, while MAO-B inhibitors are used for the reductionof the progression of Parkinson’s disease and of symptomsassociated with Alzheimer’s disease. In Figure 1, all clinicalMAO inhibitors reported in the literature are depicted.The past 30 years have witnessed the discovery of severalselective MAO inhibitors, which display greater affinitytowards only one isoform. They could be classified intoreversible or irreversible [3]. Compounds belonging to thefirst generation of MAO inhibitors were mechanism-based inactivators: they acted via formation of reactive elec-trophilic intermediates which covalently modified the pro-tein structure. Most of these derivatives also interactedwith P450s leading to hepatotoxicity. A second seriousside effect that occurs with irreversible ones is theso-called ‘cheese effect’ which is characterized by hyper-tensive crises induced by elevated dietary tyramine levelsresulting from MAO inhibition [4]. Such disadvantages ledto the identification of new reversible inhibitors ofMAO-A (i.e., RIMAs).The recent discovery of three-dimensional structures of
hMAO-A and hMAO-B with their corresponding inhibitorsshows overall similarity in their crystalline forms, but impor-tant differences can be outlined in oligomeric states and activesite structures [5,6]. In fact, hMAO-B crystallizes as a dimer,whereas hMAO-A as a monomer. In detail, the active siteof hMAO-B is characterized by a generally hydrophobicdipartite cavity with a substrate entrance cavity (~ 290 A3)connected to a larger substrate-binding cavity (~ 420 A3).Ile199 was identified as an important structural elementbecause it acts as a gate that allows the accessibility to thesecond cavity. In the closed conformation, Ile199 physicallyseparates the two cavities, whereas in the presence ofbulky ligands it adopts an open conformation. Bindingof clinical inhibitors such as rasagiline and (R)-deprenylinduces a midspan type of cavity pushing Ile199 into theopen conformation.
Although MAOs are widely distributed in various organs,most of the studies concerning their functional propertiesand involvement in pathological processes have been mainlyfocused on the CNS. In the periphery, MAO-A andMAO-B are differently expressed in a variety of organs:MAO-A is predominant in heart, adipose tissue and skinfibroblasts, MAO-B is the major form found in platelet andlymphocytes, whereas both isoenzymes are expressed inkidney and liver.
Due to the importance of these isoforms in modulatingneurotransmitter physiological activity, MAO inhibitorshave been developed as important tools in the therapy of sev-eral neuropsychiatric diseases and important breakthroughshave been reached. In fact, it is well known that impairedneurotransmission is connected to mental diseases such asdepression and generalized anxiety disorders, and susceptibil-ity to stress. The majority of antidepressants presently used aredesigned to affect one or both of the most important neuro-transmitter systems of the brain (NA and 5-HT): it is possibleto inhibit their neuronal re-uptake or limit their degradationleading to an increase in their synaptic concentration(MAO-A inhibitors) [7].
Currently, a new molecule named CX157 (3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin-10,10-dioxide) is indevelopment for the treatment of major depressive disorder.This investigational compound is a unique molecule withpotent and specific MAO-A inhibiting activity in mammaliantissues (3.3 nM in human brain) [8].
Furthermore, the observation that hMAO-B levels inhumans increase four to fivefold on aging represents arationale for the involvement of hMAO-B in age-relatedneurological disorders such as Parkinson’s and Alzheimer’sdiseases [9-11]. Increased hMAO-B activity would be expectedto diminish dopamine concentration and to release catalyticreaction products (H2O2). While dopamine seems to beinvolved in (R)-synuclein aggregation which is implicated inthe etiology of Parkinson’s disease, high levels of H2O2 inthe cell may promote apoptotic signaling events and thedevelopment of Parkinson’s disease. Therefore, inhibition ofhMAO-B should allow a sort of neuroprotection against thiskind of bioactivation. In fact, agents that specifically limitthe activity of hMAO-B are likely to act as neuroprotectants.Indeed, treatment of pre-Parkinson’s patients with selec-tive hMAO-B inhibitors has been shown to be effective inreducing the development of this neurodegeneration.
A disadvantage of the first selective hMAO-B inhibitor,(R)-deprenyl, was related to its chemical structure: it is meta-bolized in vivo to methamphetamine compounds which areknown to be endowed with a strong sympathomimetic acti-vity. One advantage of rasagiline, therefore, was that it wasnot an amphetamine derivative and showed no sympathomi-metic activity. Rasagiline [N-propagyl-1(R)-aminoindan] isnow approved by the FDA in the US for treatment of patientswith beginning stages of Parkinson’s disease [11]. In particular,rasagiline potently suppresses apoptotic cell death initiated by
Article highlights.
. The development of human monoamine oxidase (MAO)inhibitors has led to important breakthroughs in thetherapy of several neuropsychiatric disorders andneurodegenerative diseases.
. Several heterocyclic structures were reported to displayselective MAO inhibitory activity.
. Known clinical MAO inhibitors were also evaluated forthe treatment of other therapeutic targets.
. MAO inhibitors were often associated with other drugsas co-adjuvants.
This box summarizes key points contained in the article.
Focusing on new monoamine oxidase inhibitors
910 Expert Opin. Ther. Patents (2010) 20(7)
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
mitochondria [12] and inhibits mitochondrial permeabilitytransition by preventing pre-apoptotic swelling of mitochon-dria, caspase-3 and nuclear PARP-1 activation, translocationof GADPH and nucleosomal DNA fragmentation. Further,rasagiline induces an increase of the anti-apoptotic Bcl-2and Ccl-xL expression [13]. Recent studies have demonstratedthat, in addition to its MAO-B inhibitor activity, it alsopossesses potent neuroprotective activity. This target wasachieved in different animal models [14]. The (S)-enantiomer
is a much less potent (three orders of magnitude) inhibitorof hMAO-B than the (R)-enantiomer of rasagiline but retainsits neuroprotective properties. The inverted chirality leads to adifferent binding of the indan ring, which is rotated by 180�
with respect to the conformation observed in the rasagilinecomplex and coupled to a shift of the Tyr326 side chain sothat the overall balance of interactions is less favorable. Thisreduced efficacy may also result from steric hindrance.These data reveal that the binding mode of (S)-enantiomer
N
O NH
HN
O
N
HN
O
Cl
N
OO
OH
Iproniazide (I) (A/B) R-(-)-Deprenyl (I) (B) Pargyline (I) (A/B)
Moclobemide (R) (A) CX157 (R) (A)
Toloxatone (R) (A)
N
N
H
Cl
Cl
O N
Clorgyline (I) (A)
Isocarboxazide (I) (A/B)
HN
NH
O
N
O
Rasagiline (I) (B)
NH
Cimoxatone (R) (A)
N
OO
O
ONC
Befloxatone (R) (A)
N
OO
O
OF3C
OH
F
S
O O CF3
O O
Figure 1. Irreversible (I), reversible (R), and selective hMAO-A and/or MAO-B (A or B or A/B) inhibitors.
Bolasco, Carradori & Fioravanti
Expert Opin. Ther. Patents (2010) 20(7) 911
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
is clearly distinguished from that of rasagiline and theother (R)-inhibitors.Another important inhibitor, currently in Phase III clinical
trials for Parkinson’s disease and in Phase II for restless legssyndrome, is safinamide ((S)-2-(4-(3-fluorobenzyloxy)benzyl-amino)propionamide methanesulfonate) [15], which com-bines multiple mechanism of action, including reversibleinhibition of hMAO-B, sodium channel blocking activity,calcium channel modulation, dopamine re-uptake inhibitionand glutamate level modulation. Inhibition of hMAO-Breduces the metabolic inactivation of dopamine in patients,while the Na+ channel blockade selectively affects those neu-rons with abnormal firing patterns and leaves normal activityunaltered. Instead, ralfinamide ((S)-2-[4-(2-fluorobenzyloxy)benzylamino] propanamide) is a sodium channel blockeruseful in the treatment of pain conditions, including chronicand neuropathic pain, migraine, bipolar disorders anddepression [16].Ladostigil ([(3R)-3-(prop-2-ynylamino)indan-5-yl]-N-pro-
pylcarbamate) is a novel neuroprotective agent being investi-gated for the treatment of neurodegenerative disorders suchas Alzheimer’s disease, Lewy body disease and Parkinson’sdisease. It acts as a reversible acetylcholinesterase (AChE)and butyrylcholinesterase (BuChE) inhibitor (in doses of35 -- 100 µmol/kg administered orally to rats, it inhibits
cholinesterase (ChE) by 25 -- 40% and antagonizesscopolamine-induced impairments in spatial memory), andas an irreversible MAO inhibitor, and combines the mecha-nism of action of drugs such as rivastigmine and rasagilineinto a single molecule. After daily administration of75 µmol/kg for 2 weeks, ladostigil does not show any motorstimulant effects but significantly reduces immobility in theforced swim test, an action consistent with that of known anti-depressants. This could result from the inhibition of bothMAO-A and MAO-B in rat brain that, under these conditions,reaches > 70%. Ladostigil also shows selectivity for brainMAO, even after 2 months of daily administration, with littleor no effect on the enzyme located in the intestinal tract or inthe liver. This property reduces the likelihood of producingthe ‘cheese effect’. Ladostigil also has antidepressant effectsand may be useful for treating depression and anxiety. In addi-tion to its neuroprotective properties, ladostigil enhances theexpression of neurotrophic factors and may be capable ofreversing some of the damage seen in neurodegenerativediseases via the induction of neurogenesis [17].
Both stereoisomers of ladostigil protect against ischemia-induced cytotoxicity in PC12 cells and reduce edema, deficitsin motor function and memory after closed head injuryin mice. These neuroprotective effects do not result fromMAO inhibition.
Lazabemide (R) (B)
N
NH
Cl
O
NH2
O
NH
NH2
OF
Safinamide (R) (B)
Ralfinamide (R) (B)
O
NH
NH2
O
F
Ladostigil (I) (B)
NH
O
O
N
R/S-Desmethylseligiline (I) (B)
HN
Figure 1. Irreversible (I), reversible (R), and selective hMAO-A and/or MAO-B (A or B or A/B) inhibitors (continued).
Focusing on new monoamine oxidase inhibitors
912 Expert Opin. Ther. Patents (2010) 20(7)
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
However, the use of these drugs has been limited by somecentrally mediated side effects such as the serotonin syn-drome, dizziness, light-headedness, blurred vision and weak-ness. In addition, it has been reported that MAO inhibitorsmay potentiate the effects of alcohol and other drugs thatslow the CNS, such as antihistamines, cold medicine, allergymedicine, sleep aids, medicine for seizures, tranquilizers,some pain relievers and muscle relaxants. So far, there is aneed for new compounds which do not show the reportednegative side effects [16].
2. Recent discoveries on MAO inhibitors
In this section, we collect all patents dealing with new hMAOinhibitors reported in the literature between July 2005 andDecember 2009, continuing our previous work in thisfield [18]. We also reported on structures and IC50 values ofthe most representative compounds.
2.1 b-CarbolinesThis invention relates to the preparation and biologicalevaluation of b-carboline type molecules from natural anddietary amino acids [19]. b-Carbolines are bioactive alkaloidsderived from indole endowed with neuropharmacologicaland neuromodulating properties. Aromatic b-carbolineshave also been studied for their effects on serotoninergic,opioide and benzodiazepine receptors and for theireffects on MAO activity [20-22]. Starting from the inhibitionresults obtained for natural b-carbolines (IC50 MAO-A~ 6.5 µM and IC50 MAO-B ~ 4.7 µM for b-carboline(R1 = R2 = R3 = H), IC50 MAO-A ~ 0.34 µM for1-methyl-b-carboline and IC50 MAO-A ~ 0.009 µM for7-methoxy-1-methyl-b-carboline) using the kynuraminebiological assay [23], these authors proposed new derivativesof general formula 1 in Figure 2 with the ability of inhibit-ing MAOs. 1,2,3,4-Tetrahydro-b-carbolin-3-carboxylic acidshowed, at 25 µM concentration, 60% of MAO-A inhibitionand 71% of MAO-B inhibition, while 1-methyl-1,2,3,4-tetrahydro-b-carbolin-3-carboxylic acid displayed only 90%of MAO-A inhibition.
2.2 Propargylated aminoindansScientists at Cooper & Dunham LLP disclosed and synthe-sized a ladostigil ester derivative (formula 2 in Figure 2) whichacts as MAO, AChE, and BuChE inhibitor in vitro [24]. MAOinhibition has been extrapolated from a radioactivity mea-surement. It can also be used as a reference standard or markerto investigate the pharmacokinetic and metabolic profile ofladostigil. Indeed, chronic administration of 2 and ladostigiltartrate to rats indicated that the former is responsible forbrain-selective MAO inhibition. MAO inhibition in plasmasamples from patients was determined by HPLC analysis.The composition may be prepared as medicament to beadministered orally, parenterally, rectally or transdermally orcould be provided with suitable delivery systems.
2.3 IsoxazolesResearchers at Helicon Therapeutics, Inc. discovered severalisoxazole derivatives of general formula 3 in Figure 2 asMAO-B inhibitors in the micromolar range useful forimproving cognitive function [25]. They also described thesynthesis and the pharmaceutical formulations of these mole-cules. They tested them in established animal models such ascontextual memory assay in mice (to investigate the neuralsubstrates mediating fear-motivated learning and study theimpact of various mutations on hippocampus-dependentmemory) [26] and object recognition assay (to evaluatedrug--compound effects on cognitive tasks) [27].
2.4 DiterpenesThe present invention refers to dietary or pharmaceutical com-positions containing tricyclic diterpenes and their derivatives ofgeneral formulas 4 and 5 in Figure 2 for the treatment of depres-sion [28]. Among several compounds reported in this patent,only three have been tested for their ability to inhibit MAOsusing benzylamine as substrate. Carnosic acid, 20-deoxo carno-sol and carnosic acid-12-methyl ether presented MAO-A inhib-itory activity in the micromolar range (4.4, 4.3 and 40.6 µM,respectively) with a discrete selectivity over MAO-B. Carnosicacid, isolated from plants (rosemary and sage) or synthesizedaccording to literature [29]; 20-deoxo-carnosol, isolated fromplants (Lepechinia urbaniana and wild sage) or synthesized;and carnosic acid 12-methyl ether, extracted from plants(sage, rosemary and Hyptis martiusii) possessed a biologicalactivity against disorders connected to impaired neurotrans-mission. The same three derivatives were also evaluated in theserotonin uptake inhibition test, in the Porsolt’s swim test [30]
in comparison with fluoxetine, and in the Marble buryingtest [31] in comparison with fluoxetine and venlafaxin. Carnosicacid has been also assayed in the light dark box test in themouse after subchronic, oral gavage described by Crawley [32]
to test its anxyolitic effect. Finally, researchers disclosedseveral pharmaceutical compositions for administering thesederivatives to humans and animals.
2.5 ImidazolesBayer Pharmaceuticals Corp. has synthesized a novel class ofimidazole derivatives of general formula 6 in Figure 2 asselective MAO-A inhibitors [33].
MAO inhibitory activity was not specifically assessed butthe biological evaluation of this scaffold as MAO-A inhibitorswas accomplished through in vitro, ex vivo and in vivo assaysthat are well known in the art to evaluate depression (forcedswim test, tail suspension test), schizophrenia (prepulse inhi-bition) and anxiety (elevated plus maze) [34] in establishedanimal models.
2.6 DithiolethionesSolvay Pharmaceuticals B.V. developed anethole dithiole-thione and other dithiolethiones (Figure 3) for the treatmentof conditions associated with dysfunction of monoamine
Bolasco, Carradori & Fioravanti
Expert Opin. Ther. Patents (2010) 20(7) 913
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
NH
NR1
R2R3
2
A2A3
A1R1
B X
Y
R1 = H, C1-6-alkyl; R2 = OH, C3-5-acyloxy, hydroxymethyl,1,3-dihydroxypropyl, C1-6-alkyl; R3 = R4 = H, OH, hydroxymethyl,C1-5-acyloxy, C1-6-alkoxy; R5 = C1-6-alkyl, hydroxymethyl, carboxy,methoxycarbonyl; R6 = H; R7 = R8 = C1-6-alkyl, carboxy, 1-6-hydroxy-C1-6-alkyl, C1-6-alkoxycarbonyl; R9 = H, hydroxymethyl, OCH3, oxo,C1-5-acyloxy; R10 = H; R11 = R12 = H, oxo
R1
R2
R3
R4
R5
R9
R10
R11
R6R7
R8
R12
O
R2
R3
O
R5
R9
R10
R11
R6R7
R8
R12
R1 = R2 = phenyl group (substituted with one or more halogens, alkyl, alkoxy, CF3, CN, NO2, Ph, alkyl sulfonyl, alkyl sulfonyl-amino,alkyl carbonyl-amino, alkyl amino-carbonyl-amino); alkyl; cyclohexyl (unsubstituted or substituted with alkyl, alkoxy, CF3, CN, one ormore fluorine); 1-naphtyl or 2-naphtyl (unsubstituted or substituted with alkyl, alkoxy, CF3, CN); benzyl (unsubstituted or substitutedon the phenyl ring with alkyl, alkoxy, CF3, CN); a5- or a 10-membered saturated, unsaturated or aromatic heterocyclic radical(unsubstituted or substituted with one or more halogens, alkyl, alkoxy, CF3, CN, NO2, Ph). R3 = H. alkyl, benzyl, chloro, bromo.X = -CONR4R5 or -CONHSO2R6. R4 = H, alkyl. R5 = alkyl or bicycloalkyl (unsubstituted or substituted with phenyl, hydroxy, benzyloxy,alkoxy, alkyl amino, F); benzyl or benzocycloalkyl (unsubstituted or substituted with hydroxy, benzyloxy, hydroxyalkyl, one or morehalogens, alkyl, alkoxy, CF3, CN, NO2). R6 = alkyl, phenyl, or benzocycloalkyl (unsubstituted or substituted with phenyl, hydroxy,benzyloxy, alkoxy, halogen)
NN
R1
R2
R3
X
R1 = R2 = H, halogen, alkyl, OCH3R3 = H, alkyl
1R1 = H, aryl, C1-6-alkyl; A1 = N,substituted alkyl; A2 = A3 = O, N;B = aryl, heteroaryl; X = carbonyl,thiocarbonyl, sulfonyl,substituted alkyl; Y = H, OH, C1-6-alkyl, aryl, heteroaryl
3
4 5
6
NH
OHN
O
HO
Figure 2. General structures of derivatives 1 -- 6.
Focusing on new monoamine oxidase inhibitors
914 Expert Opin. Ther. Patents (2010) 20(7)
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
neurotransmission (in particular, MAO-B activity) [35]. Thegoal of this invention is to develop new bioactive molecules,structurally unrelated to those presently available and withfew side effects. Some related compounds were said to inhi-bit D-amino-acid oxidase, the enzyme that stereoselectivelydeaminates D-amino acids generating H2O2 as MAOs. Ithas now been found that this scaffold potently inhibitsMAO-B activity in cellular extracts derived from culturedrat striatal astroglial cells, whereas no significant effect isobserved on MAO-A activity (Table 1).
In addition, 3H-1,2-dithiole-3-thione (7) and its lipo-philic analog 5-(4-methoxyphenyl)-3H-1,2-dithiole-3-thione(8, anethole dithiolethione) [36] have been tested for theirability of inhibiting MAO activity (Table 2).
All synthesized compounds were fully characterized andembodied in different pharmaceutical formulations in orderto be administered at 0.1 -- 100 mg/kg of patient’s bodyweight.MAO activity was determined using the Amplex Red MAO kitassay based on the fluorescence method described by Zhou andPanchuk-Voloshina [37]. Neonatal rat striatal cells were used as a
source of both MAO isoforms and clorgyline and L-deprenylwere considered as reference drugs.
2.7 OxoisoaporphinesThis invention relates to the synthesis (with high yields in atwo-steps process) and biological evaluation of selectivehMAO-A inhibitors of oxoisoaporphine derivatives (9 inFigure 3), isomers of widely distributed natural oxoaporphinesafter oxidation of specific alkaloids (aporphines) [38,39]. Thesecompounds have been little characterized for their biologicalproperties and could represent the first example of isoquino-line alkaloids able to inhibit hMAO activity [40]. In the past,these derivatives have been synthesized because of their abilityto act as photoconductors or semiconductors. The effects ofthe test compounds on the enzymatic activity of hMAO iso-forms have been evaluated by a fluorimetric method follow-ing an experimental protocol previously described by theauthors [41]. The biological evaluation on hMAO activity hasbeen investigated by measuring their effects on the productionof H2O2 from p-tyramine (a common substrate for both
SS
S
SS
S
H3CO
D3T
N
O
R
R1
R2
R3
9R = R1 = R3 = H, OCH3;R2 = H, OCH3, NH2, NHCH2CH2 (4-HO-Ph);R1 = R2 = -OCH2O-
X
NH
N
O
R1
R2
R4
R3
R7
R6
R5
O
O
OCH3
NH
S
O
O
NH2
1110R1 = R2 = H, C1-6-alkyl, fused heterocycleR3 = R4 = H, fused cyclopropane ringX = CH, N; R5 = R6 = R7 = C1-3-alkyl, alkoxy,alkylaryl
7
Anethole dithiolethione8
Figure 3. General structures of derivatives 7 -- 11.
Bolasco, Carradori & Fioravanti
Expert Opin. Ther. Patents (2010) 20(7) 915
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
Table 1. hMAO-B inhibition of dithiolethione derivatives.
SS
S
R1
R2
R1 R2 MAO-B % inhibition
(10-5 M)
4-Hexyloxyphenyl H 100
H ON
O
81
H ON
83
Phenyl
O
ON
N
65
4-Methylphenyl
O
ON
N
74
4-Methylphenyl 4-Methylpiperazinyl 54
H -CH=CH-(4-diethylaminophenyl) 52
H -CH=CH-(2-quinolinyl) 56
Phenyl -S(CH2)2CH(CH3)NH-2-propynyl 25
Phenyl -S(CH2)2CH(CH3)NH-2-propynyl 100
Phenyl -S(CH2)2CH(CH3)NH-2-propynyl 95
Phenyl -S(CH2)2CH(CH3)N(CH3)-2-propynyl 81
Phenyl -S(CH2)2CH(CH3)N(CH3)-2-propynyl 75
Phenyl -S-CH2-(4-methylphenyl) 71
Table 2. Percent inhibition of MAO activity after administration of ADT, D3T and reference drugs.
Concentration (mM) Total MAO activity
(% inhibition)
MAO-B activity
(% inhibition)
MAO-A activity
(% inhibition)
L-Deprenyl ADT L-Deprenyl ADT D3T Clorgyline ADT
0.1 56 14 80 15 - 100 -0.3 73 35 97 40 - - -1 79 60 100 73 2 - -3 - 70 - 89 6 - -10 - 81 - 96 24 - 330 - 85 - 100 59 - 14100 - - - - 82 - -300 - - - - 92 - -1000 - - - - 91 - -
3DT: 3H-1,2-dithiole-3-thione; ADT: Anethole dithiolethione.
Focusing on new monoamine oxidase inhibitors
916 Expert Opin. Ther. Patents (2010) 20(7)
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
hMAO-A and hMAO-B), using the Amplex Red MAO assaykit and microsomal MAO isoforms prepared from insect cellsinfected with recombinant baculovirus containing cDNA(BTI-TN-5B1 -- 4) inserts for hMAO-A or hMAO-B. Theproduction of H2O2 catalyzed by MAO isoforms can bedetected using 10-acetyl-3,7-dihydroxyphenoxazine (AmplexRed reagent), a non-fluorescent and highly sensitive probethat reacts with H2O2 in the presence of horseradish peroxi-dase to produce a fluorescent product, resorufin. The testdrugs (new compounds and four reference inhibitors) wereunable to react directly with the Amplex Red reagent,which indicates that these drugs do not interfere withthe measurements.
Structure--activity relationships were inferred from the dataof enzymatic experiments reported in Table 3. One compounddisplayed MAO-A picomolar inhibitory activity (inferior tothe most active reference drug) and, for it, the authors alsoreported ‘dose-concentration’ responses against hMAO-A.Other derivatives showed the best activity and selectivitytowards this isoform.
2.8 Prolinamide derivativesResearchers at Glaxo Group Ltd proposed, in some embodi-ments, new prolinamide derivatives of general formula 10
in Figure 3 as dual agents (sodium channel modulators andMAO-B inhibitors), which are said to be useful in the treat-ment of different conditions such as Alzheimer’s disease andsenile dementia [42]. They synthesized and characterizedthem by 1H NMR, HPLC and mass spectral studies. Therationale of this association could be found in the importanceof modulating the use-dependent voltage-gate sodium chan-nels in several CNS pathologies (bipolar disorders, mania,depression, schizophrenia). They affect neuron depolariza-tion, calcium influx and release of neurotransmitters. Theprotocol also described the test for evaluating MAO-B inhibi-tion by a fluorescent-based end point assay using benzylamineas substrate (Amplex Red reagent) but biological data arenot reported.
2.9 Benzo-heteroarylsulfonamidesThese two inventions by Janssen Pharmaceutica N.V weredirected to the use of benzo-heteroaryl sulfamide derivativesfor the treatment of depression, including both monotherapyand co-therapy with at least one antidepressant [43,44]. In2007, compounds of general formula 11 in Figure 3 were syn-thesized, characterized and assayed in vivo to predict theirability to treat mood disorders (dominant--submissive compe-tition) [45] and antidepressant activity (mouse tail suspensionand mouse forced swim tests). It is important to note thatthe NMRI mice used in these tests do not respond to allantidepressants in this model; rather, they exhibit selectivesensitivity to 5-HT re-uptake inhibitors and some tricyclicantidepressants. The lack of activity of tested drugs in thismodel would only suggest that the compound does notinhibit 5-HT re-uptake. In 2009, instead, researchers
synthesized a new class of anxiolytic agents based on this phar-macophore and tested them in vivo (mice): elevated plusmaze [34] and four plate tests [46]. MAO inhibitory activitywas not specifically assessed for all compounds.
2.10 Diphenyl ether derivativesResearchers at Orchid Research Laboratories Ltd pro-posed new MAO-A inhibitors of formulas 12 -- 22 in Figure 4
assayed by the kynuramine deamination test [47]. Com-pounds 12 -- 17 exhibited MAO inhibitory activity lowerbut still comparable to clorgyline at 1 µM concentration,while compounds 18 -- 22 reached the same results only at10 µM concentration.
2.11 Benzopyran derivatives7-Hydroxycoumarin derivatives also represented an effectivestrategy in the generation of reversible MAO inhibitors [48-50].Functionalization of the hydroxyl group modulated the MAOinhibitory activity and selectivity [51-53].
Researchers at Newron Pharmaceuticals SpA synthesizedand fully characterized novel aminoalkyl- and amidoalkyl-benzopyran derivatives of general formula 23 in Figure 5 asreversible MAO-B inhibitors, with IC50 in the nano- ormicromolar range, assayed in vivo (mice) and in vitro for theprevention and the treatment of CNS degenerative disorders.They did not possess any relevant effect on MAO-A activity.They could be administered alone or in conjunction withone or more therapeutic agents.
These coumarin analogs have shown to possess differentpharmacological properties and similar compounds, whereinthe substituents on the pyran ring do not contain either anamido or an amino group, and have been patented recently.MAO enzyme activity was evaluated in vitro after extractionof both isoforms from rat brain and administration of14C-serotonin (for MAO-A) and 14C-phenylethylamine (forMAO-B) through a radioenzymatic assay (Table 4). In orderto investigate whether the test compounds were irreversibleor reversible MAO-B inhibitors, the authors performedtime-dependent experiments for calculating their associationkinetics. At last, they also evaluated ex vivoMAO-B inhibitionadministering such compounds orally to mice. Results showedthat this scaffold acted as a potent, reversible and short-acting MAO-B inhibitor with full recovery of the enzymaticactivity 8 -- 16 h after the administration.
Structurally similar benzopyranone derivatives (24 inFigure 5) were also designed by Ache Laboratorios Farmaceu-ticos S/A for preventing or treating diseases associated withMAOs. These compounds could be obtained syntheticallyby conventional chemical routes or be contained in a stan-dardized pharmaceutical product (plants belonging to thefamily of Passifloraceae) and for this reason they could existas C-glycosylated flavonoids (schaftoside, isoschaftoside, vitexin,isovitexin, isovitexin-2¢¢-O-b-glucopyranoside, isoorientin-2¢¢-O-b-glucopyranoside). The authors considered that thequantity of active principle may vary between ~ 1 and
Bolasco, Carradori & Fioravanti
Expert Opin. Ther. Patents (2010) 20(7) 917
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
Table 3. hMAO inhibition reported for oxoisoaporphine derivatives and reference drugs.
Compound IC50 hMAO-A IC50 hMAO-B Ratio
N
O
H3CO
H3CO
OCH3
27.32 ± 1.18 µM* z > 3.66#
N
O
H3CO
H3CO
OCH3
OCH3
13.65 ± 0.34 nM* z > 7326#
N
O
H3CO
OCH3
44.37 ± 2.25 nM* z > 2253.77#
N
O
OCH3
O
O
723.48 ± 52.36 µM* * > 0.14#
N
O
H3CO
OCH3
HO
OCH3 835.75 ± 49.75 pM* z > 119,653.01#
N
O
H3CO
H3CO
OCH3
1.23 ± 0.08 µM* z > 81.30#
Ratio: hMAO-A selectivity index = IC50 (hMAO-B)/IC50 (hMAO-A). Each IC50 value is the mean ± s.e.m. from five experiments.
Level of statistical significance: *P < 0.01 versus the corresponding IC50 values obtained against hMAO-B, as determined by ANOVA/Dunnett´s.zInactive at 100 µM (the highest concentration tested).§50 µM (the highest concentration tested).{Inactive at 1 mM (the highest concentration tested).#Values obtained under the assumption that the corresponding IC50 against hMAO-B is the highest concentration tested.
Focusing on new monoamine oxidase inhibitors
918 Expert Opin. Ther. Patents (2010) 20(7)
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
500 mg and, for ease of demonstration, reported on in vitroMAO activity inhibition tests carried out with a standardizedpharmaceutical Passiflora incarnata product using kynuramineas substrate.
Another invention relates to novel, synthetic or isolatedfrom plant, coumarin ether derivatives of general formula 25
in Figure 5 for preventing and treating disorders connectedto impaired neurotransmission. DSM Ip Assets B.V. thought
these dietary/pharmaceutical compositions as ‘conditionimprovers’. Among them, they reported biological data aboutMAO inhibition of the racemic obliquin (26), isolated fromplants [54] or synthesized according to literature (Table 5) [55].The colorimetric MAO assay and the higher specificity forMAO-B were reported. Obliquin displayed, in the concen-tration range 10-7 -- 10-4, a better inhibition of MAO-B(8.3 -- 91.5%) over MAO-A (2 -- 24.1%). Further, it has
Table 3. hMAO inhibition reported for oxoisoaporphine derivatives and reference drugs (continued).
Compound IC50 hMAO-A IC50 hMAO-B Ratio
N
O
H3CO
OCH3
HO
34.75 ± 1.28 nM* z > 2877.70#
N
O
H3CO
H3CO
OCH3
OCH3 13.36 ± 0.54 nM* z > 7485.03#
N
O
OCH3
NH
H3CO
OCH3 HO 2.12 ± 0.07 µM* § > 23.58#
N
O
OCH3
H2N
H3CO
OCH3 9.81 ± 0.26 µM* § > 5.10#
Clorgyline 3.97 ± 0.75 nM* 63.41 ± 1.20 µM 15,972.29
(R)-deprenyl 68.73 ± 4.21 µM* 17.32 ± 1.96 nM 0.00025
Iproniazid 6.56 ± 0.76 µM 7.54 ± 0.36 µM 1.15
Moclobemide 361.38 ± 19.37 µM* { > 2.77#
Ratio: hMAO-A selectivity index = IC50 (hMAO-B)/IC50 (hMAO-A). Each IC50 value is the mean ± s.e.m. from five experiments.
Level of statistical significance: *P < 0.01 versus the corresponding IC50 values obtained against hMAO-B, as determined by ANOVA/Dunnett´s.zInactive at 100 µM (the highest concentration tested).§50 µM (the highest concentration tested).{Inactive at 1 mM (the highest concentration tested).#Values obtained under the assumption that the corresponding IC50 against hMAO-B is the highest concentration tested.
Bolasco, Carradori & Fioravanti
Expert Opin. Ther. Patents (2010) 20(7) 919
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
been assayed even in the Porsolt’s swim test, a validated animalmodel for depression which responds to enhancement of thetransmission of serotonin, dopamine and NA [30], in theMarble burying test for anxiety-like or obsessive behavior [31]
and in the serotonin uptake inhibition and labeled citalopramdisplacement test.
2.12 a-Aminoamides (safinamide derivatives)Safinamide, as described above, combines multiple mecha-nisms of action and could present unexpected side effects [56].For these reasons, new mono or polydeuterated derivatives(27 in Figure 5) have been synthesized, characterized andassayed for their ability of inhibiting MAO-B and modulatingNa+ and Ca+2 channel activity. It has been proven thatsuch derivatives can be administered alone or with a secondtherapeutic agent having the same mechanism of action of
safinamide. This invention relates to the manufacturing ofdifferent kits to treat Parkinson’s disease and restless legs syn-drome. A number of studies suggest that the fundamentalpathophysiology of this last syndrome involves mechanismsof iron and dopamine transport and turnover (in particulariron deficiency and its potential effects on dopamine systemactivity), thus, demonstrating the clinical use of dopaminepromoting MAO-B inhibitors such as selegiline, rasagilineand safinamide. These disclosed compounds were evaluatedonly for metabolic stability in vitro against human livermicrosomes (20 mg/ml) by calculating their t1/2 values [57].
2.13 Pyrazole derivativesBayer Pharmaceuticals Corp. has synthesized novel substi-tuted pyrazole derivatives (including their enantiomers andconformers) of general formula 28 in Figure 5 useful in the
HCl HCl HCl
12 13
O
S
NH
H2N
O OCH3
S
O
14
O
S
NH
H2N
O OCH3
O
O
F
15
O
NH
Cl
N
O
O
O
16
O
NH
Cl
N
O
O
O
O
S
NH
H2N
O
S
O
OCH3
17
O
NH
Cl O
O
NH
O
Figure 4. Diphenyl ether derivatives 12 -- 22.
Focusing on new monoamine oxidase inhibitors
920 Expert Opin. Ther. Patents (2010) 20(7)
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
treatment of psychiatric disorders including schizophrenia,depression and anxiety [58,59]. Demonstration of their activityhas been accomplished through in vitro, ex vivo and in vivoassays well known in the art about established animal models.The forced swim [30] and the tail suspension tests have beenused to assess the efficacy of antidepressant compounds, whileeffects on schizophrenia and anxiety have been studiedthrough the prepulse inhibition and the elevated plus mazetests [60,61]. MAO inhibitory activity was not specificallyassessed for all compounds.
Other pyrazole compounds were evaluated as inhibitors ofMAO-B enzyme activity and could be useful for improvingcognitive function and for treating psychiatric disorders inanimals. The MAO enzymatic assay was performed accordingto the fluorometric method described by Matsumoto et al. [23]with slight modifications. These compounds showed MAO-B
inhibitory properties at 0.1 -- 10 µM, typically at 5 -- 100%.Most of them demonstrated selectivity for MAO-B overMAO-A. The ability of a compound to modulate cognitivebehavior can be evaluated using a specific assay which meas-ures memory after contextual fear conditioning. Compoundswere dissolved in 1% DMSO/PBS and administered intra-peritoneally in a volume of 8 ml/kg 20 min before training.The ability of a compound to modulate cognitive behaviorcan also be evaluated using the object recognition assay.Specifically, some compounds of this scaffold, injected20 min before training, significantly enhanced contextualmemory in mice.
2.14 Pyridine derivativesThese two patents, written in Japanese, reported on thesynthesis, characterization and biological evaluation of
O
NH
18
Cl O
H2N
O OCH3
HCl
20
O
N
O
O
S
NO
S
COOH
21
O
N
O
O
S
NHO
S
Cl
22
HCl
O
H2N
S
NHO
O
OH3CO
O
S
NH
H2N
O
HCl
OCH3
O
O
19
Cl
Figure 4. Diphenyl ether derivatives 12 -- 22 (continued).
Bolasco, Carradori & Fioravanti
Expert Opin. Ther. Patents (2010) 20(7) 921
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
O R4
R3
N
O
R1
R2
OR
O
OOH
R2
HO
R1
R3
OH
23
3
ROO
R1
R
O3
25R1 = H,OH,(E )-methyl-but-2-enyl;R2 = methyl, 3-(4,5-dihydro-5,5-dimethyl-4-furanon-2-yl)-2-(E/Z )-butenyl, (E/Z )-3,7-dimethylocta-2,6-dienyl,7-hydroxy-3,7-dimethyl-2-octen-6-on-yl,(E/Z , E/Z )-11-acetyl-oxy-3,7,11,11-tetramethyl-undeca-2,7-dien-10-onyl; -R3 = H, -O-C(H)(C(CH3)2(H)-O-C(O)CH3)-CH2-
O O
O
O
26
FO
NHY1 Y2
Y3 Y4
O
NH2
R1Y5 N
N
R
R1
R2
A B
X
29R = H, alkyl, alkenyl, alkynyl, halo; R1 = alkyl, aryl, alkoxy, aryloxy,
halogen; X = CO, SO2; Y = alkylene; A = saturated ring, aromatic ring
N
R
NX
Y
R1
A
N
R
N
R1
XY
A
for substituents see Table 4 24
R1 = R2 = H, carbohydrate;R3 = H, OH
27R1 = CH3, polideuterated CH3Y = H, D
28R = R1= unsusbstitutedor substituted aryl and heteroaryl;R2 = H,OH,C1-3-alkoxy;A = different-linkers;B = sulfonyl,carbonyl;X = benzyl, aryl, heteroaryl, C1-8-alkyl
Figure 5. General structures of derivatives 23 -- 29.
Focusing on new monoamine oxidase inhibitors
922 Expert Opin. Ther. Patents (2010) 20(7)
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
pyridine derivatives of general formula 29 in Figure 5 asselective MAO-B inhibitors useful for treatment ofParkinsonism [62,63].
The second series of pyridine derivatives is claimed to haveBBB permeability as centrally acting drugs and contrast agentsfor MRI.
2.15 PolyprenolsThis invention, written in Russian, referred to therapeuticagents for reducing MAO over activity based on a scaffoldof polyprenols of general formula 30 in Figure 6 [64]. The treat-ment is characterized by one or more doses of polyprenols inamounts ranging from 1 to 150 mg/day. Biological data foreach compound are reported in Russian.
2.16 Biphenyl derivativesMerck Frosst Canada Ltd synthesized and characterized138 biphenyl derivatives of general formula 31 in Figure 6 asreversible inhibitors of recombinant hMAOs using thekynuramine assay. They could be used alone or in associa-tion with other therapeutic agents [65]. Biological data arenot reported.
2.17 Benzyloxy derivativesThe invention related to benzyloxy derivatives of general for-mula 32 in Figure 6 was prepared enantiomerically pure andcharacterized with mass spectrometry [66-68]. The tested com-pounds acted as MAO-B inhibitors and were especially usefulfor the treatment and prevention of Alzheimer’s diseaseand senile dementia. MAO enzymatic assay was performedusing a spectrophotometric method described by Zhou andPanchuk-Voloshina [37]. Clorgyline and L-deprenyl wereused as reference drugs. Data were not reported but theauthors stated that the IC50 values ranged from 1 to 0.02 µMagainst MAO-B.
2.18 Oxazolidinone derivativesThe structural template for this scaffold was derived fromcimoxatone, toloxatone and befloxatone (currently in
Phase III clinical trials for depression) [69-74]. Isozyme selectiv-ity is dramatically improved by replacing the central phenylgroup of befloxatone with larger heteroaromatic moieties.SAR studies demonstrated the strict requirement for theR-configuration of the stereogenic center of the methoxy-methyloxazolidinone group and a para-substituent on the arylring for good inhibition activity. In particular, oxazolidinoneswith amine and ether substituents in the 5-position ofthe nucleus have been described as having potent MAOinhibitory activity [75-77].
Certain antibacterial compounds containing an oxazolidi-none ring have been described in the literature and theirmechanism of action has been fully investigated [78]. Line-zolid, N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, was the first approvedantimicrobial oxazolidinone for clinical use in the US. How-ever, inhibition of MAO is a potential cause of manyunwanted side effects, and so this property was minimizedin each potential antibacterial agent.
The first invention related to a scaffold of sulfur-containing substituted 2,3,5-trifluorophenyl oxazolidinonesof general formula 33 in Figure 6 and to the process of theirsynthesis. The enzymatic assay for hMAO-A was performedby a spectrophotometer and was based on the formation ofa colored reaction product [79].
In this patent, the authors at AstraZeneca UK Ltddescribed a class of bi-aryl compounds containing one oxazo-lidinone and one isoxazoline ring, bearing ether or substitutedether side chains on the isoxazoline and a triazole ring onthe oxazolidinone, endowed with acceptable levels of MAOinhibition whilst having useful antibacterial activity. Theysynthesized and characterized novel compounds of generalformula 34 in Figure 6 and also provided a process for pre-paring a pharmaceutically-acceptable salt or an in vivo hydro-lysable ester thereof. These molecules displayed a goodspectrum of activity in vitro against pathogenic bacteria interms of the MIC, but they were also assayed on humanliver MAO enzymes expressed in yeast as described in theliterature [80]. From the results, it was possible to extrapolate
Table 4. MAO inhibition of coumarin derivatives.
Compound IC50 MAO-A (mM) IC50 MAO-B (mM)
4-[(Hydrazinocarbonyl)methyl]-7-benzyloxy-2H-chromen-2-one 1.4 0.04
4-[(Aminocarbonyl)methyl]-7-(3-fluoro-benzyloxy)-2H-chromen-2-one 70 0.05
4-[(Dimethylaminocarbonyl)methyl]-7-(3-chloro-benzyloxy)-2H-chromen-2-one > 100 0.04
4-[(Dimethylaminocarbonyl)methyl]-7-benzyloxy-2H-chromen-2-one 15.3 0.08
4-Aminoethyl-7-(3-chloro-benzyloxy)-2H-chromen-2-one 1.9 0.01
4-[(Methylamino)methyl]-7-(3-fluoro-benzyloxy)-2H-chromen-2-one 13.5 0.02
4-(2-Aminoethyl)-7-(3-chloro-benzyloxy)-2H-chromen-2-one 31.8 0.25
4-[(Methylamino)methyl]-7-(3-chloro-benzyloxy)-2H-chromen-2-one 5.9 0.01
4-[2-(Methylamino)ethyl]-7-(3-chloro-benzyloxy)-2H-chromen-2-one 74 0.30
Bolasco, Carradori & Fioravanti
Expert Opin. Ther. Patents (2010) 20(7) 923
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
Table 5. MAO inhibition of pyridine derivatives.
Compound Concentration MAO-A
(% inhibition)
MAO-B
(% inhibition)
O
Cl
N
N
10 µM 13 87
O
Cl
N
N
10 µM -- 59
O
N
N
F
F
10 µM -- 39
O
N
N
F
10 µM 6 92
O
N
N
Cl
10 µM -- 80
O
Cl
F
N
N
10 µM -- 92
Focusing on new monoamine oxidase inhibitors
924 Expert Opin. Ther. Patents (2010) 20(7)
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
Table 5. MAO inhibition of pyridine derivatives (continued).
Compound Concentration MAO-A
(% inhibition)
MAO-B
(% inhibition)
O
N
N
Cl
Cl
10 µM 9 77
O
N
N
CF3
10 µM 5 31
O
OCH3
OCH3
N
N
10 µM 4 --
SO
Cl
O
N
N
10 µM 4 6
O
Cl
N
N
10 µM 9 11
H
O
Cl
N
N
N
1 µM 10 1
Bolasco, Carradori & Fioravanti
Expert Opin. Ther. Patents (2010) 20(7) 925
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
that the introduction of a 4-alkyltriazole generally demon-strated lower MAO-A inhibition than the unsubstitutedtriazole analogs. The most active derivative is (5S)-3-[3-fluoro-4-[6-((5S)-5-[[(2-hydroxyethyl)]methyl]-4,5-dihydroisoxazol-3-yl)pyridin-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one.Successively, researchers at Ferrer Internacional, SA devel-
oped a novel class of cyano piperidinyl-phenyl-oxazolidinonesand 1(2H)-tetrazol-5-yl-phenyl-oxazolidinones, which wereactive against bacteria, but with a weak MAO inhibitory acti-vity. They also investigated and characterized different poly-morphic forms of some of them by X-ray diffractionspectrum, equilibrium solubility and differential scanningcalorimetry. MAO inhibition assay was performed on com-pounds reported in Table 6 using membranes from SF9 cells(a cell line derived from pupal ovarian tissue of Spodopterafrugiperda) expressing both isoforms. Kynuramine was usedas substrate for the fluorimetric reaction.Metaxalone (35 in Figure 6), 5-[(3,5-dimethylphenoxy)
methyl]-2-oxazolidinone, is an orally administered skeletalmuscle relaxant with a relatively low toxicity [81]. Researchersat Auspex Pharmaceuticals, Inc. synthesized and fully charac-terized novel metaxolone derivatives of general formula 36
in Figure 6 substituted with hydrogen or deuterium. Deutera-tion of pharmaceuticals to improve pharmacokinetic, phar-macodynamic and toxicity profiles has been demonstratedwith some classes of drugs. These derivatives were assayedfor their in vitro liver microsomal stability and the resultsshowed that the deuterated ones possessed an improved degra-dation half-life (37%), compared to the non-isotopicallyenriched drug. This invention also related to the inhibition
of CYPs or MAO isoforms by this scaffold itself or in com-bination with other agents (i.e., MAO inhibitors). MAO-Ainhibition and oxidative turnover were carried out spectro-photometrically using the method described by Weyler [82,83],while MAO-B inhibition was performed as reported byUebelhack et al. [82,83].
2.19 Deuterated derivativesResearchers at Auspex Pharmaceuticals, Inc. studied and dis-closed two classes of deuterated compounds which are usefulfor the management of psychological or post-traumatic stressdisorders of general formulas 37 and 38 in Figure 6 [84,85].These derivatives were synthesized and characterized to actthrough different mechanism of actions, and their ability toinhibit MAOs was also investigated. Biological data are notreported, but they stated that the decrease in activity ofMAO isoform, in some embodiments, was greater than about50% when compared to the corresponding non-isotopicallyenriched compounds.
2.20 Fluoro substituted amphetamine derivativesResearchers at the University of Tubingen proposednovel fluoro substituted derivatives of amphetamine (39in Figure 6) endowed with low neurotoxicity or hallucinogeneffects, which could have a therapeutic action againstParkinson’s disease in animal models [86,87]. They stated thatthese compounds possess a better pharmacological profileand could be administered alone or in association withother drugs (i.e., MAO inhibitors, selegiline). In the patent,they reported on synthesis, characterization data of newcompounds and biological assays to evaluate their effects on
Table 5. MAO inhibition of pyridine derivatives (continued).
Compound Concentration MAO-A
(% inhibition)
MAO-B
(% inhibition)
H
O
Cl
N
N
N
1 µM 9 2
O
N
N
F
10 µM 14 63
1 µM 5 17
0.1 µM 1 8
Focusing on new monoamine oxidase inhibitors
926 Expert Opin. Ther. Patents (2010) 20(7)
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
H ( )n
OH
n = 8 – 2030
R1
R2
R
R3
R = CONH2, CN; R1= CH3, -CH2-CH2-;R2 = OH, NH2; R3 = polyfluoroalkyl, polyfluorophenyl
31
Y X NO
O
HN
F
F F
R
O
NO
O
R2
N
NN
R
R1
N
NO
O
R3
ONH
OO
35 36R = H, D
ON
OOR
RR
R
R
R
R
R
R
R R
R
RR
O
NR2
R3
R4
R5
O
NH
O
R1
33X = CH, N; Y = O, SO, SO2,
HOCH2CON; R = alkyl, alkoxy, NH-alkyl
34R = H, halogen, CN, halomethyl, methylthio, alkynyl;R1 = R2 = H, F, Cl, CF3; R3 = alkyl, substituted alkyl
32R1 = halogen, haloalkyl, haloalkoxy,cyano; R2 = R3 = R4 = R5 = H, halogen
Figure 6. General structures of derivatives 30 -- 39.
Bolasco, Carradori & Fioravanti
Expert Opin. Ther. Patents (2010) 20(7) 927
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
the Parkinson-induced symptoms on mice. MAO inhibitoryactivity was not specifically assessed for all compounds.
2.21 MAO inhibitors obtained from plantsFive additional inventions relate strictly to methods and com-positions involving the inhibition of MAO and/or otherenzymes using processed plant products.The Morinda citrifolia fruit juice is reported to be able to
increase the inhibition of the MAO enzyme and/or cathecol-O-methyl transferases without causing negative side effectswhen the composition is administered to a mammal. Extractsmay be also obtained from the leaves, stem, seeds and roots byfirst chopping the raw material. After removing insolublecomponents through filtering, the solvent is removed and acomplex mixture is obtained (quercetin and rutin are pre-sent in amounts by weight ranging from 0.01 to 10% of thetotal formulation or composition). This formulation couldbe administered to a patient orally, intravenously andsystemically [88].Gingko biloba extracts and compositions, which contain
20 -- 30% flavonoid glycosides, 2.5 -- 4.5% gyngkolides,2 -- 4% bilobalides, < 10% proanthocyanidines and < 10 ppmalkylphenol type compounds (EGb 761), could act as regulat-ing MAO activity agents and dopamine restoring nutraceuticalsfor the treatment of Parkinson’s disease and MPTP-inducedParkinsonism [89].
A dry and a fluid extract of Rhodiola rosea L., free of undesir-able tannins of the pyrogallol group, could possess inhibitoryactivity against MAOs and other enzymes (phosphodiesterasesand COMT) [90]. According to the method of Zhou andPanchuk-Voloshina [37], the fluid extract inhibited MAO-Awith an IC50 ~ 4.5 µM and MAO-B with an IC50 ~ 3.5 µM.
Another invention [91] relates to the use of Chinese herbsBuguzhi (Psoralea corylifolia L.) and Fuling (Poria cocosWolf.) extracts in formulations for the treatment of depres-sion and related symptoms (the weight portion of Buguzhiextract and Fuling extract ranges from 1:1 to about 1:7).The pharmaceutical composition comprises about 95% furo-coumarins (7 -- 9% of psoralen and about 6 -- 8% of isopsor-alen) and about 57 -- 62% of polysaccharides. The inventionrelates to the field of pharmaceutical composition, dietarysupplements, health products and related formulations.Kong et al. [92] reported on in vitro experiments designed totest inhibition of rat brain MAO activity by psoralen and iso-psoralen. However, the actual effectiveness thereof is not yetproven. Rat brain mitochondrial fractions were prepared fol-lowing the procedure described by Schurr and Livne [93].MAO activity was assessed by the spectrophotometer asdescribed by Yu et al. [94]. It can be noticed that oral adminis-tration of the extract at doses of 200 and 150 mg/kg sig-nificantly inhibited MAO-A and MAO-B activities intreated animals, 45.49 and 64.01%, respectively. In order to
N
N
N
O
O
R
R
R
R
R
R
O
OR
R
RR
R
R
R
R
R
37R = H, D
O
O
N
RR
R
RR
R
R
RR
R
R
R
R
R
38R = H, D
R
R
NR1
R1R
R
39R = H, F, CH3R1 = H, CH3
Figure 6. General structures of derivatives 30 -- 39 (continued).
Focusing on new monoamine oxidase inhibitors
928 Expert Opin. Ther. Patents (2010) 20(7)
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
investigate the antidepressant effects of the pharmaceuticalcomposition, tail suspension test [95], forced swimmingtest [30] in mice and chronic mild stress (CMS) were used.In the CMS model, the recovery of sucrose intake, inhibitionof brain MAO-A and -B activities, and reduction in cortisol
level in CMS-treated rats are used as indicators of effectivenessof antidepressant drugs [96]. The reversal of CMS-inducedbehavioral change reported is the result of MAO activity inhi-bition and normalization of the hypothalamic-pituitary-adrenalaxis hyperactivity. The antidepressant actions could make
Table 6. Ki values for both MAO isoforms by some oxazolidinone derivatives and linezolid.
Compound MAO-A Ki (mM) MAO-B Ki (mM)
SO
O
HCH3
O
NNN
F F
F 84 --
SO
O
HCH3
O
O
O
N NN
F
F F
3000 --
N NNN
O
O
HCH3
O
O
OH
F
F F
195 --
OO
O
HCH3
O
N NN
F
FF
268 --
O
O
HCH3
O
NC N NN
F
1.05 2.45
NO
O
HN
FCH3
O
NN
N N
74.20 14.20
NO
O
HN
FCH3
O
NN
N N
O
37.10 10.10
NO
O
HN
FCH3
O
NN
N N
OH
28.80 8.10
O N NO
O
HN
FCH3
O
Linezolid
6.96 0.48
Bolasco, Carradori & Fioravanti
Expert Opin. Ther. Patents (2010) 20(7) 929
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
Buguzhi and Fuling extracts potentially valuable drugs for thetreatment of elderly depression. The components (psoralenand isopsoralen) of the produced Buguzhi extract were analyzedby HPLC, using ultraviolet as detection.Finally [97], some authors investigated the inhibitory acti-
vity against MAO-B, superoxide dismutase, NOS and AchEof an extract of Lotus enriched in procyanidins. Biologicaldata and methods are reported in Chinese.
3. New targets of MAO inhibitors
MAO inhibiting agents have also been extensively studied fortreating or preventing other pathologies they are validated for.
3.1 Isocarboxazid and migraineA pharmaceutical composition of isocarboxazid (Figure 1) in arapid-release formulation (sublingual or intranasal spray, fastdissolving tablets, biphasic or injectable formulations, viscouscontrolled release formulations), which enables the release ofisocarboxazid within 30 sec after being administered sub-sequently to onset of symptoms, has been patented for itscapability of preventing or treating migraines alone or in asso-ciation with other agents [98,99]. In fact, it has been suggestedthat MAOIs (phenelzine and isocarboxazid) may also have abeneficial effect against certain symptoms associated withmigraines, even if their mechanism of action is not very welldefined. The authors reported on a double-blind, multi-center, placebo-controlled study performed to evaluate theeffect of 20 or 40 mg doses of isocarboxazid in the acutetreatment of migraine (with or without aura) and chronictension-type headache.
3.2 Safinamide and its derivatives in the therapy of
glaucomaThe present invention is directed to compounds of generalformula 40 in Figure 7, which are MAO inhibitors, and totheir use in treating disorders of the outer retina resultingfrom acute or chronic degenerative conditions of the eye [100].Certain MAO inhibitors, especially the selective
MAO-B ones, have demonstrated possessing neuroprotective/neurorescuing properties in a number of models and to beable to inhibit induction of apoptosis. In fact, in the retina,selegiline and desmethylselegiline protected ganglion cellsfrom NMDA-induced excitotoxicity [101], while L-deprenylpreserved the same cells after optic nerve crush [102], andclorgyline had an effect on photoreceptor rhythms of diskshedding and autophagic degradation [103]. Safinamide andits synthesized derivatives were potent and selective inhibitorsof MAO-B with an IC50 in the submicromolar--nanomolarrange and no relevant effect on MAO-A in vitro (Table 7).After oral administration in mice, the tested compoundsbehaved as short-acting MAO-B inhibitors with full recoveryof activity 8 -- 16 h after a single-dose administration.The neuroprotective activity of these selective MAO-B
inhibitors was evaluated in the rat photo-oxidative-induced
retinopathy model, because cellular damage resulting fromthis kind of stress leads to cell death by apoptosis [104]. Dosingwith safinamide resulted in a dose-dependent protection ofretinal function, which was demonstrated through differentexperiments. Such compounds can be also incorporated intovarious types of ophthalmic formulations for selective deliveryto the eye.
3.3 Rasagiline and bruxismAnother invention related to a method for preventing ortreating bruxism by administering a therapeutically effectiveamount of an MAO inhibitor (rasagiline) that increases dopa-minergic activity [105]. Bruxism, otherwise known as teethclenching or grinding, is a commonly occurring conditioninvolving forceful contact between the biting surfaces of theupper and lower teeth. It has been found that compoundsthat act as dopaminergic agents can be effectively used inthe prevention and treatment of bruxism and thereby alleviateor eliminate one or more related symptoms. The compoundsof the present invention can be used in combination withother drugs that provide additional therapeutic benefits.Two patients with symptoms and evidence of bruxism weretreated with 0.5 -- 1.0 mg of rasagiline one time per day fora total of 30 days. Both treated patients exhibited a reductionor elimination of one or more symptoms or evidence ofbruxism, including the reduction or elimination of headache,jaw pain and migraine.
3.4 Rasagiline and multiple system atrophyResearchers at Teva Pharmaceuticals USA, Inc. disclosedseveral pharmaceutical compositions for the treatment andalleviation of symptoms of multiple system atrophy(MSA) [106]. This progressive neurodegenerative disease doesnot possess a determined cause, occurs sporadically and causesParkinsonism, cerebellar, pyramidal autonomic and urologi-cal dysfunction [107]. There is no specific treatment for thevarious features of MSA and therapy tends to be aimed atmitigating the Parkinsonism. While levodopa and dopamineagonists have been tested with mixed results, rasagiline dem-onstrated potent neuroprotective activity, in addition to itsMAO-B inhibition, in in vitro and in vivo experiments. Thisinhibitor, administered from 0.5 to 5 mg/day, was evaluatedin several established animal models to assess its neurotoxicityand its effects on rat motor behavior and in a mouse model ofMSA. Biological data are accurately reported.
3.5 Rasagiline and glaucomaRecently, rasagiline has been incorporated in a method fortreating subjects afflicted with glaucoma or suffering fromretinal ganglion cell (RGC) damage [108]. Glaucoma is a groupof ocular diseases characterized by progressive damage to theeye partly due to elevated intraocular pressure (IOP). Addi-tionally, it could be characterized by RGC death, axonloss and an excavated appearance of the optic nerve head.RGC death mechanisms in experimental animal models of
Focusing on new monoamine oxidase inhibitors
930 Expert Opin. Ther. Patents (2010) 20(7)
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
glaucoma and human glaucoma have been shown to involveapoptosis [109]. Further, while L-deprenyl was suggested forthe treatment of glaucoma, the effects of rasagiline on thispathology had not previously been studied. Results showedthat rasagiline had a positive effect on RGC survival assay ina rat model of chronically elevated IOP. This indicates thattreatment with rasagiline eliminated some processes whichcontributed to ganglion death and increased protectionagainst loss of RGCs consequently reducing severity of glau-coma symptoms, for example, limiting atrophy of the opticnerve. In conclusion, the aims of this study were to presentevidence that rasagiline, administered in the form of eyedrops, penetrates the inner layers of the eye by examiningthe extent of MAO inhibition in the retina, determinerasagiline doses which inhibit MAO-A and MAO-B in the
retina, and assess the systemic penetration of rasagiline byexamining the extent of MAO inhibition in internal organssuch as liver and brain. The results showed that local MAOinhibition in the retina was higher than the level of inhibitionobserved in the liver, while inhibition of the brain enzymeswas similar to the retina ones.
3.6 Desmethylseligiline and ischemic/hypoxic
damageThe present disclosure is directed to methods for reducingthe neuronal damage associated with cerebrovascular diseasecaused by ischemia or hypoxia, such as stroke or cerebraledema, by administering R(-)-desmethylselegiline (R(-)DMS),S(+)-desmethylselegiline (S(+)DMS) or a combination of thetwo [110]. Selegiline can be used as a prophylactic treatment
Table 7. MAO inhibition of safinamide derivatives.
Compound IC50 MAO-A (mM) IC50 MAO-B (mM)
2-[[4-(3-Chloro-benzyloxy)-benzyl]-methyl-amino]-acetamide 50 0.04
(S)-2-[4-(2-fluoro-benzyloxy)-benzylamino]-propionamide 228 0.18
(S)-2-[4-(4-fluoro-benzyloxy)-benzylamino]-propionamide 93 0.06
(S)-2-[4-(3-chloro-benzyloxy)-benzylamino]-propionamide 114 0.03
(R)-2-[4-(3-chloro-benzyloxy)-benzylamino]-3-hydroxy-propionamide > 100 0.11
(S)-2-[4-hexylmethoxy-benzylamino)-propionamide 301 0.03
(S)-2-[4-(3-fluoro-benzyloxy)-benzylamino]-3-hydroxy-propionamide 100 0.14
(S)-2-[4-(3-chloro-benzyloxy)-benzylamino]-3-hydroxy-propionamide 84 0.04
(S)-2-[[4-(3-chloro-benzyloxy)-benzyl]-methyl-amino]-3-propionamide 82 0.06
40
O
N
RR1
R2
O
R4
R3
A1
A2
A3
A QN
R
R1
NH2
R2
41
42
RR7
R6
R5
R4R3
R2 R1
43
A1
A2
A3
A QN
R R1
Figure 7. General structures of novel MAO inhibitors 40 -- 43 with new therapeutic targets (for substituents, see the
corresponding reference).
Bolasco, Carradori & Fioravanti
Expert Opin. Ther. Patents (2010) 20(7) 931
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
for brain tissue in a rat model when it is administered beforehypoxia/ischemia [111]. Specifically, it was found to exert protec-tive effects against ischemic/hypoxic damage in the striatum andthalamus areas of the brain, probably by reducing oxidativeneuronal damage, increasing the amount of the enzymesuperoxide dismutase and/or reducing dopamine catabolism.Selegiline is ~ 128 times more potent as an inhibitor ofMAO-B relative to MAO-A, whereas R(-)DMS is about97 times more potent as an inhibitor of MAO-B relative toMAO-A. The purity of both synthesized enantiomers wasdetermined by HPLC, mass spectroscopy, IR and 1H NMRstudies. The neuroprotective effect of both R(-)DMS and S(+)DMS was also examined using several experimental models(also compared with two other MAO inhibitors, pargylineand clorgyline). They resulted as effective neuroprotectants,inhibited transport of released dopamine at the neuronal syn-apse, and enhanced the relative activity of this neurotransmitterat the synapse. In this context, S(+)DMS is more potentthan selegiline which, in turn, is more potent than R(-)DMS.For these reasons, S(+)DMS is the most preferred drugwith regard to the treatment of hypodopaminergic conditionssuch as attention deficit/hyperactivity disorder (AD/HD).In vivo, both enantiomers demonstrated activity in inhibitingMAO-B, indicating that these enantiomers are able to crossthe BBB.
3.7 Ladostigil and MSLadostigil tartrate has been also studied (3.3 -- 5 mg/kg/day)for the treatment of MS, a chronic, inflammatory CNS dis-ease characterized by demyelization of neural axons in thebrain and spinal cord [112]. Among several hypotheses, anautoimmune one is supported by the experimental allergicencephalomyelitis (EAE) model of MS. Researchers reportedon in vitro and in vivo studies from which it is possible toextrapolate that this drug decreased both the incidence andseverity of EAE through the observation of its clinical signsin mice post EAE-induction. Moreover, dose-dependentMAO inhibition was observed (81 -- 99% inhibition ofMAO-B and 55 -- 60% inhibition of MAO-A). The ChEactivity recorded was mostly AChE (47 -- 52% of AChE inhi-bition in brain and 60 -- 65% in blood), while BuChE wasreduced to an extent of 35 -- 42%.
3.8 Clorgyline and cardiovascular diseasesA very interesting and innovative invention relates to theadministration of MAO inhibitors in the prevention andtreatment of heart failure, post-ischemic oxidative stress andmyocyte hypertrophy [113]. In spite of various known treat-ment and preventive methods, heart failure remains a majorcause of worldwide mortality. A variety of MAO inhibitorsare useful for practicing the methods of the present invention.MAO-A (or -B) inhibitors administered in accordance withthe invention are those which do not give rise to thepotentially harmful side-reaction called ‘cheese-effect’. Therationale for this therapy depends on the fact that MAO-A
is the prevalent isoform in the heart, and the majority of theenzyme is situated in the cardiomyocytes. In the peripheraltissues, MAO protects the body by oxidizing blood-derivedamines or by preventing their entry into the bloodstreambecause they have major implications in the progression ofcompensated hypertrophy to left ventricular (LV) dilationand failure. Accordingly, the present invention provides thatinhibition of MAOs, such as MAO-A, effectively preventsor retards this progression, improves myocardial function,and may also limit the loss of viable myocardial cells due toincreased oxidative stress and pro-apoptotic signaling. Theeffects of MAO-A inhibition under pharmacological condi-tions on the LV hypertension development were also tested.As described, after 3 weeks, wall thickness was increased inclorgyline-treated mice and LV function was significantly bet-ter. Moreover, mice showed reduced levels of hypertrophy.These results demonstrate that inhibiting MAO-A by admin-istering a therapeutically effective amount of an MAO inhib-itor prevents or reduces maladaptive LV hypertrophy,chamber dilation and LV dysfunction in pressure-overloadedhearts. Furthermore, the administration of the MAO-A inhib-itor clorgyline results in reduced levels of apoptosis in heartcells after 6 weeks: it is able to impact the pro-apoptotic sig-naling cascade preventing caspase-3 activation and oxidativestress in cardiomyocytes [114,115].
3.9 Lazabemide and pargyline derivatives in the
treatment of obesityThere are four patents related to a new application of alreadyknown or new MAO inhibitors for the treatment of obesityand/or associated pathologies (diabetes, cardiometabolicdisorders) [116-119]. In particular, MAO-B inhibitors, clinicallyuseful in the treatment of CNS disorders, have unexpectedlyshown an anti-obesity activity (reduction of adipose tissue,promotion of weight loss), alone or in association with anappetite suppressant or a lipase inhibitor (synergic effect).
The former patents by Jenrin Discovery disclosed this newtherapeutic target using several especially clinically testedMAO-B inhibitors and a large array of new synthesized andcharacterized derivatives reported in literature (see referencestherein). Specific relevance was attributed to synthesis, phar-maceutical formulations and MAO-B inhibitory activity oflazabemide derivatives of general formula 41 in Figure 7,which could be used for cardiometabolic disorders.
The last patents proposed a new mechanism of action for anovel scaffold of derivatives of general formula 42 in Figure 7
and pargyline derivatives (43, N-benzyl-N-propargyl-amines),which prevented the deposition of adipose tissue becauseMAO enzymes are located in a number of peripheral (non-CNS) tissues, including adipocytes. That is why it was neces-sary to limit the BBB permeation and reduce central sideeffects mediated by these compounds introducing polar func-tions (i.e., quaternary salts or acid substituents) in the phar-macophore. Biological data are not presented but theauthors stated that only representative compounds have been
Focusing on new monoamine oxidase inhibitors
932 Expert Opin. Ther. Patents (2010) 20(7)
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
tested and showed to be active in the micromolar rangeagainst MAO-B isoform.
3.10 Befloxatone and its derivatives in the treatment
of capillary pigmentationEfficacy of inhibitors of MAO to fight the whiteness of hair isshown in another patent by L’Oreal, FR. A cosmetic processfor the capillary pigmentation of the superficial body growths,such as hair, could include the use of inhibitors of MAO(befloxatone and its derivatives) [120]. It is known that specificenzymes participating in the synthesis and degradation ofcatecholamines (MAO) are expressed by melanocytes, andtheir catabolism products could be toxic against the samecells [121].
3.11 Pargyline derivatives and hair follicle growthResearchers at Cutech s.r.l suggested new compositions (oralor topical application) comprising MAO inhibitors (pargylineand its derivatives) and a cosmetically acceptable carrier(water, alcohols, polyols, oil bodies) [122]. Surprisingly, it hasbeen observed that these inhibitors have a strong effect oncell proliferation and increase hair follicle growth. At thesame time, they delay the decline of the catagen phase andenlarge the anagen one during which the growth of the hairfollicles take place. Finally, the number of proliferative cellsis significantly increased, while cell apoptosis remains at thesame level. The results obtained in this study and supportedby detailed experimental data reveal that MAO inhibitorsmay represent effective agents for fighting many kinds ofdiseases associated with disorders of hair follicles.
4. New associations with other drugs ofclassical MAO inhibitors
While there is only one patent dealing with selective MAO-Binhibitors, different associations among MAO-A inhibitorsand other drugs have been published.
An alternative triple therapy, which comprehends a selec-tive re-uptake inhibitor of serotonin, an MAO inhibitor anda phosphodiesterases inhibitor (in a composition containingglabridin, resveratrol and quercetin), has been proposed fortreating mental disorders [123].
Moreover, two inventions provided pharmaceuticalcompositions comprising droxidopa ((2R,3S)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid) alone orin association with MAO inhibitors and others drugs for thetreatment of orthostatic hypotension [124], mood disorders(depression), sleep disorders (narcolepsy, insomnia) or AD/HD [125]. Droxidopa is a psychoactive drug and a syntheticamino-acid precursor which acts as a crossing BBB prodrugto the neurotransmitters NA and epinephrine [126].
On the contrary, new indolylalkyl derivatives of pyrimidi-nylpiperazine [127] are reported to be useful for alleviating,preventing and treating anxiety, depression and sexual
dysfunction due to their effect on the serotonin system.They have been synthesized and characterized for a monother-apy or a co-therapy in conjunction with MAO inhibitors andother drugs.
Researchers at Ellneuroxx Ltd disclosed novel dihydroxy-phenylalanine derivatives and pharmaceutical compositionscontaining an association of these compounds with sele-giline and other drugs for the treatment of movement andneurodegenerative disorders [128].
Janssen Pharmaceutica, N.V. proposed new carbamatederivatives to be used in association with a conventional anti-depressant (in particular, RIMA) [129]. These compounds havebeen shown to have antidepressant action and an activating orenergizing effect in both animal models and in studies inhumans, even though the precise mechanism of action is notcompletely understood.
Dimebolin hydrochloride is an antihistamine drug whichhas been used clinically in Russia since 1983. Recently, dime-bolin has attracted renewed interest after showing positiveeffects on people suffering from Alzheimer’s disease throughmultiple mechanisms of action [130]. Subsequently, it hasbeen associated with a reversible inhibitor of MAO-A inclinical therapy for the treatment of Alzheimer’s disease [131].
At Cypress Biosciences, Inc., researchers studied the combi-nation of antidepressants (i.e., RIMAs) with a 5-HT antagonistto increase the tolerability of the latter compound [132].
Inventors at the University of Montana [133] have discov-ered that amphetamines and their derivatives, alone or in asso-ciation with MAO inhibitors or tricyclic antidepressant, couldreduce, if administered within 16 h, the occurrence of neuro-nal cell damage and death caused by transient cerebral hyp-oxia and ischemia. In the patent, in vivo and in vitroexperimental models and data were reported to justify thedose-dependent neuroprotective response.
Researchers at Janssen Pharmaceutica N.V. [134] proposednovel carbamate derivatives (25 -- 400 mg/day) with antide-pressant activity, which could also be useful, in associationwith MAO inhibitors, for the treatment of sexual dysfunctionin human female or males. The effect reported was confirmedby literature studies [135]. The precise mechanism of action isnot completely understood, but they were assayed in an animalmodel that supported an increased central catecholaminergicactivity after administration.
Researchers at Richter Gedeon Vegyeszeti Gyar RT pro-posed a new combination between voltage-gated sodiumchannel blocker and an MAO-B inhibitor to gain anincrease effect in several pathologies [136] (Alzheimer’s disease,Parkinson’s disease, chronic pain and epilepsy) [137]. In thereported experiments (inhibition of the spinal reflex, inhibi-tion of maximal electroshock seizures, behavioral study,Morris maze, in vivo neuroprotective effect in an entorhinal cor-tex lesion model), they surprisingly found a marked increase inthe sodium channel blocking activity of some compoundswhen an MAO-B inhibitor (rasagiline or (R)-deprenyl) wassimultaneously administered. In particular, an increased level
Bolasco, Carradori & Fioravanti
Expert Opin. Ther. Patents (2010) 20(7) 933
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
of cholinergic synapses, which may be particularly advantageousin Alzheimer’s disease, followed the treatment.
5. New administration routes of classicalMAO inhibitors
In order to achieve prolonged and useful levels of drug in theblood without reaching adverse effects, some authors focusedtheir attention on the improvement of the manufacturing ofdosage forms (controlled-release drug delivery systems) oftransdermal patches of rasagiline [138].
6. New synthetic process of MAO inhibitors
It is known that the large scale preparations of safinamideand ralfinamide according to the methods described inthe prior art contain two undesired impurities, that is,(S)-2-[3-(3-fluorobenzyl)-4-(3-fluorobenzyloxy)-benzylamino]propanamide and (S)-2-[3-(2-fluorobenzyl)-4-(2-fluoroben-zyloxy)-benzylamino]propanamide, respectively [139,140]. Thisfact is of particular relevance as these impurities showed avery high toxicity against the CYP system which is stronglyundesirable in early preclinical phase. This patent related toa new synthetic process for the large scale production of safi-namide and ralfinamide (their salts, enantiomers and racemicmixture) with high purity degree (content of benzyl deriva-tives impurities lower than 0.01 -- 0.03%), better yields andreaction work-up, and a safer biological profile. The syntheticschemes were accurately described.
7. Expert opinion
The patents reported, published starting from July 2005 tothe end of 2009, are tripled in comparison with the previousreview [18] and show that the interest in this field is constantlyincreasing. Furthermore, the description of the three-dimensional crystallographic structure of the hMAO-B andmore recently of the hMAO-A led to the discovery of newlead compounds useful as MAO selective inhibitors.Currently, the major interest is devoted to the study
of MAO-B inhibitors used as agents for the treatment ofParkinson’s disease, Alzheimer’s disease and neurologicaldisorders probably due to the progressive ageing of the
population. Several drugs with MAO-A inhibitory activityare used for the treatment of depression and new psychiatricdisorders. The new compounds, obtained some by synthesisand others by extraction methods of processed plant, are char-acterized by different structures (b-carbolines, aminoindanes,isoxazoles, diterpenes, imidazole derivatives, dithiolethiones,oxoisoaporphines, prolinamide derivatives, benzoheteroaryl-sulfonamides, benzopyran derivatives, pyrazole and pyridinederivatives, oxazolidinones) and by reversible or irreversibleand selective inhibitory activity.
The reported patents regarding the new target of MAOinhibitors, alone or in association with other drugs, high-lighted the role of radical scavengers of the MAO inhibitorsin preventing and treating migraines, glaucoma, bruxism,MSA, ischemic/hypoxic damage, MS, cardiovascular disease,obesity, and pigmentation and growth of hair follicles.
Moreover, some patents licensed new administration routesor synthetic processes to enhance the activity of alreadyknown MAO inhibitors.
Finally, we draw attention to results obtained by usinghMAOs in comparison to those evaluated with rMAOs [141]
or established animal models. In fact, in the literature, humanbrain, liver and blood platelets have been little used as hMAOsources to screen inhibitors, because of the easy accessibility ofrat and bovine brain or liver for in vitro studies. But species-dependent differences [5] (single amino-acid substitutionsmay induce deep changes in the secondary and tertiary struc-tures of these isoforms) have been reported by differentauthors for several classes of compounds [142]. Therefore, thedivergences found, after extrapolating data on MAO inhibi-tion from different species sources to the human enzyme,could have a deep impact on the development of new andselective hMAO inhibitors.
Dedication
This paper is dedicated to the memory of our colleagueFrancisco Orallo.
Declaration of interest
The authors state no conflict of interest and have received nopayment in preparation of this manuscript.
Focusing on new monoamine oxidase inhibitors
934 Expert Opin. Ther. Patents (2010) 20(7)
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
Bibliography
1. Singer TP, Von Korff RW, Murphy DL.
Monoamino oxidase: structure, function
and altered functions. Academic:
New York; 1979
2. Wouters J. Structural aspects of
monoamine oxidase and its reversible
inhibition. Curr Med Chem
1998;5:137-62
3. Da Prada M, Kettler R, Keller HH,
et al. From moclobemide to Ro
19-6327 and Ro 41-1049: the
development of a new class of reversible,
selective MAO-A and MAO-B inhibitors.
J Neural Transm Suppl 1990;29:279-92
4. Strolin-Benedetti M, Dostert PL.
Monoamine oxidase: from physiology
and pathophysiology to the design and
clinical application of reversible
inhibitors. Adv Drug Res
1992;23:65-125
5. Hubalek F, Binda C, Khalil A, et al.
Demonstration of isoleucine 199 as a
structural determinant for the selective
inhibition of human monoamine
oxidase B by specific reversible inhibitors.
J Biol Chem 2005;280(16):15761-6.
Data deposition: www.pdb.org
(PDB ID code 2BK3)
6. Son SY, Ma J, Kondou Y, et al.
Structure of human monoamine
oxidase A at 2.2-A resolution:
the control of opening the entry for
substrates/inhibitors. Proc Natl Acad
Sci USA 2008;105:5739-44. Data
deposition: www.pdb.org
(PDB ID code 2Z5X)
7. Pacher P, Kecskemeti V. Trends in
the development of new antidepressants.
Is there a light at the end of the tunnel?
Curr Med Chem 2004;11:925
8. Fowler JS, Logan J, Azzaro AJ, et al.
Reversible inhibitors of Monoamine
oxidase-A (RIMAs): robust, reversible
inhibition of human brain MAO-A by
CX157. Neuropsychopharmacology
2010;35(3):623-31
9. Carreiras MC, Marco JL. Recent
approaches to novel anti-Alzheimer
therapy. Curr Pharm Design
2004;10(25):3167-75
10. Drukarch B, Muiswinkel FL. Drug
treatment of Parkinson’s disease.
Biochem Pharmacol 2000;59:1023-31
11. Guay DR. Rasagiline (TVP-1012): a new
selective monoamine oxidase inhibitor for
Parkinson’s disease. Am J
Geriatr Pharmacother 2006;4(4):330-46
12. Youdim MBH, Gross A, Finberg JP.
Rasagiline [N-propagyl-1R-(+)-
aminoindan], a selective and potent
inhibitor of mitochondrial monoamine
oxidase B. Br J Pharmacol
2001;132(2):500-6
13. Weinreb O, Bar-Am O, Amit T, et al.
Neuroprotection via pro-survival protein
kinase C isoforms associated with
Bcl-2 family members. FASEB J
2004;18(12):1471-73 and references
therein
14. Blandini F, Armentero MT, Fancellu R,
et al. Neuroprotective effect of rasagiline
in a rodent model of Parkinson’s disease.
Exp Neurol 2004;187(2):455-9
15. Caccia C, Maj R, Calabresi M, et al.
Safinamide: from molecular targets to
a new anti-Parkinson drug. Neurology
2006;67:S18-23
16. Zhang S-H, Blech-Hermoni Y,
Faravelli L, Seltzer Z. Ralfinamide
administered orally before hind paw
neurectomy or postoperatively provided
long-lasting suppression of spontaneous
neuropathic pain-related behaviour in the
rat. Pain 2008;139(2):293-305
17. Van der Schyf CJ, Geldenhuys WJ,
Youdim MBH. Multifunctional drugs:
ladostigil, an anti-Alzheimer drug.
In: Ana Martinez, editor, Medicinal
Chemistry of Alzheimer’s Disease.
Transworld Research Network, Kerala,
India; 2008. p. 1-20
18. Bolasco A, Fioravanti R, Carradori S.
Recent development of Monoamine
oxidase inhibitors. Exp Op Ther Patents
2005;15(12):1763-82
19. Consejo Superior de Investigaciones
Cientificas, ES. Preparation and
Monoamino oxidase inhibition of
beta-carboline from natural products.
WO2007085679; 2007
20. Kim H, Sablin SO, Ramsay RR.
Inhibition of monoamino oxidase A
by beta carboline derivatives.
Arch Biochem Biophys
1997;337:137-42
21. Nelson DL, Herbert A, Petillot T, et al.
[3H]Harmaline as a specific ligand of
MAO-A from rat and bovine brains.
J Neurochem 1979;32(6):1817-27
22. Herraiz T, Chaparro C. Human
monoamine oxidase is inhibited by
tobacco smoke: beta-carboline alkaloids
act as potent and reversible inhibitors.
Biochem Biophys Res Commun
2005;326:378-86
23. Matsumoto T, Suzuki O, Furuta T,
et al. A sensitive fluorometric assay for
serum monoamine oxidase with
kynuramine as substrate. Clin Biochem
1985;18:126-9
24. Teva Pharmaceutical Industries, Ltd.
Preparation of (propargylated)
aminoindans as monoamine oxidase
and acetylcholinesterase inhibitors for
treatment of psychiatric and neurological
disorders. US2007203232; 2007
25. Helicon Therapeutics, Inc. Preparation
of isoxazole compounds as monoamine
oxidase B inhibitors. WO2009029632;
2009
26. Phillips RG, LeDoux JE. Differential
contribution of amygdala and
hippocampus to cued and contextual
fear conditioning. Behav Neurosci
1992;106:274-85
27. Van der Schyf CJ, Geldenhuys WJ,
Youdim MBH. Multifunctional drugs:
Ladostigil, an anti-Alzheimer drug. In:
Medicinal Chemistry of
Alzheimer’s Disease. Ana Martinez,
editor, Transworld Research Network,
Kerala, India; 2008. p. 1-20
28. Dsm Ip Assets B.V. Dietary or
pharmaceutical compositions containing
tricyclic diterpenes and derivatives thereof
for the treatment of depression.
EP1925302; 2008
29. Cui YX, Xiao Q, Tu PF. A concise
approach to the synthesis of carnosic acid
type diterpenes. Chin Chem Lett
2001;12(3):203-4
30. Porsolt RD, Le Pichon M, Jalfre M.
Depression: a new animal model sensitive
to antidepressant treatments. Nature
1977;266:730-2
31. Poling A, Cleary J, Monaghan M.
Burying rats in response to aversive and
nonaversive stimuli. J Exp Anal Behav
1981;35:31-44
32. Crawley AJN.
Neuropsychopharmacological specifity
of a single animal model for the
behavioural action of benzodiazepines.
Bolasco, Carradori & Fioravanti
Expert Opin. Ther. Patents (2010) 20(7) 935
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
Pharmacol Biochem Behav
1981;15:695-9
33. Bayer Pharmaceuticals Corp. Imidazole
derivatives for the treatment of
psychiatric disorders.
WO2006060202; 2006
34. Handley SL, Mithani S. Effects of
alpha-adrenoceptor agonist in a
maze-exploration model of
fear-motivated behavior.
Naunyn-Schmiedeberg’s Arch Pharmacol
1984;327:1-5
35. Solvay Pharmaceuticals B.V. Anethole
dithiolethione and other dithiolethiones
for the treatment of conditions associated
with dysfunction of monoamine
neurotransmission.
WO2006089861; 2006
36. Christen MO. Anetole dithiolenthione:
biochemical considerations.
Methods Enzymol 1995;252:316-23
37. Zhou M, Panchuk-Voloshina N.
A one-step fluorometric method for the
continuous measurement of monoamine
oxidase activity. Anal Biochem
1997;253:169-74
38. Universidade de Santiago de Compostela,
ES. Use of oxoisoaporphines and the
derivatives thereof as selective inhibitors
of monoamino oxidase A.
WO2009034216; 2009
39. Shamma M, Slusarchyk WA. The
aporphine alkaloids. Chem Rev
1964;64:59-79
40. Bembenek ME, Abell CW, Chrisey LA,
et al. Inhibition of monoamine oxidases
A and B by simple isoquinoline
alkaloids: racemic and optically active
1,2,3,4-tetrahydro-,3,4-dihydro- and fully
aromatic isoquinolines. J Med Chem
1990;33:147-52
41. Yanez M, Fraiz N, Cano E, Orallo F.
Inhibitory effects of cis- and
trans-resveratrol on noradrenaline and
5-hydroxytryptamine uptake and on
monoamine oxidase activity.
Biochem Biophys Res Comm
2006;344:688-95
42. Glaxo Group Limited. Prolinamide
derivatives as sodium channel
modulators. WO2007042250; 2007
43. Janssen Pharmaceutica, N.V. Preparation
of benzo-heteroaryl sulfamide derivatives
for the treatment of depression.
US2007191449; 2007
44. Janssen Pharmaceutica N.V. Use of
benzo-fused heterocycle sulfamide
derivatives for the treatment of anxiety
disorders. WO2009120189; 2009
45. Malatynska E, Knapp RJ.
Dominant-submissive behavior as models
of mania and depression.
Neurosci Biobehav R 2005;29:715-37
46. Aron C, Simon P, Larousse C,
Boissier JR. Evaluation of a rapid
technique for detecting minor
tranquilizers. Neuropharmacol
1971;10:459-69
47. Orchid Research Laboratories Limited.
MAO-A inhibitors with a diphenyl
ether-substructure for treatment of
mental disorders. WO2009030968; 2009
48. Ache Laboratorios Farmaceuticos S/A.
Pharmaceutical compositions comprising
benzopyranones for treating diseases and
disturbances associated to monoamine
oxidase. WO2009121155; 2009
49. Newron Pharmaceuticals S.p.A.
Preparation of substituted
aminoalkyl- and amidoalkyl-benzopyran
derivatives as selective and reversible
MAO-B inhibitors.
WO2006102958; 2006
50. Dsm Ip Assets B.V. Novel agents for
preventing and treating disorders
connected to impaired
neurotransmission.
WO2006042441; 2006
51. Catto M, Nicolotti O, Leonetti F, et al.
Structural insights into monoamine
oxidase inhibitory potency and
selectivity of 7-substituted coumarins
from ligand- and target-based
approaches. J Med Chem
2006;49:4912-25
52. Carotti A, Altomare C, Catto M, et al.
Lipophilicity plays a major role in
modulating the inhibition of monoamine
oxidase B by 7-substituted coumarins.
Chem Biodivers 2006;3:134-49
53. Chimenti F, Secci D, Bolasco A, et al.
Synthesis, molecular modelling and
selective inhibitory activity against
human monoamine oxidases of
3-carboxamido substituted coumarins.
J Med Chem 2009;52:1935-42
54. Koorbanally NA, Randrianarivelojosia M,
Mulholland DA, et al. Bioactive
constituents of Cedrelopsis microfoliata.
J Nat Prod 2002;65:1349-52
55. Bohlmann F, Franke H. Isolation of
obliquin from Phaenocoma
prolifera. Phytochemistry
1973;12:726-7
56. Concert Pharmaceuticals, Inc.
Preparation of alpha-amino amide
derivatives for treatment of disease.
WO2009054964; 2009
57. Obach RS. Prediction of human
clearance of twenty-nine drugs from
hepatic microsomal intrinsic clearance
data: an examination of in vitro half life
approach and nonspecific binding to
microsomes. Drug Metab Disp
1999;27:1350-9
58. Bayer Pharmaceuticals Corp. Pyrazole
derivatives for the treatment of
psychiatric disorders.
WO2006060201; 2006
59. Helicon Therapeutics, Inc. Preparation
of substituted pyrazoles as MAO-B
inhibitors. US2007203154; 2007
60. Swerdlow NR, Geyer MA. Using an
animal model of deficient sensorimotor
gating to study the pathophysiology and
new treatments of schizophrenia.
Schizophr Bull 1998;24:285-301
61. Pellow S, File SE. Anxiolytic and
anxiogenic drug effects on exploratory
activity in an elevated plus-maze:
a novel test of anxiety in the rat.
Pharm Biochem Behav 1986;24:525-9
62. Fujifilm Finechemicals Co., Ltd.
Preparation of pyridine derivatives as
MAO inhibitors and pharmaceutical
compositions containing them.
JP2008239520; 2008
63. Fujifilm Corp. Pyridine analogs with
blood brain barrier permeability.
JP2009249346; 2009
64. Roshchin VI, Sultanov VS. Medicinal
agent for treating patients suffering
from diseases caused by the
monoaminooxidase excessive activity and
a method for treating patients suffering
from diseases caused by the monoamine
oxidase excessive activity.
RU2366430; 2009
65. Merck Frosst Canada, Ltd. Preparation
of aryl derivatives as reversible inhibitors
of monoamine oxidase a and b.
WO2006133559; 2006
66. Hoffman-La Roche, Inc. Preparation of
benzyloxyphenoxyalkylcarboxamides and
related compounds as monoamine
oxidase-B inhibitors.
US2005288367; 2005
67. Hoffmann-La Roche, Inc. Preparation of
1-(4-benzyloxyphenyl)pyrrolidin-2-one
derivatives as monoamine oxidase B
inhibitors. US2006025599; 2006
Focusing on new monoamine oxidase inhibitors
936 Expert Opin. Ther. Patents (2010) 20(7)
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
68. Hoffmann-La Roche AG. Process for
preparing 4-pyrrolidinylphenyl benzyl
ether derivatives as MAO-B inhibitors.
WO2006097197; 2006
69. Astrazeneca AB. Preparation of
3-(4-(2-dihydroisoxazol-3-ylpyridin-5-yl)
phenyl)-5-triazol-1-ylmethyloxazolidin-2-
ones as MAO inhibitors for the
treatment of bacterial infection.
WO2005116024; 2005
70. Ferrer Internacional, S.A.
[Fluoro(cyanopiperidinyl)phenyl]
oxazolidinone as monoamine oxidase
inhibitor and its preparation,
pharmaceutical compositions and
use in the treatment of bacterial
infections. WO2009077484; 2009
71. Ferrer Internacional, S.A.
{[(2)H-Tetrazol-5-yl]phenyl}
oxazolidinones as monoamine oxidase
inhibitors and their preparation,
pharmaceutical compositions and use
in the treatment of bacterial infections.
WO2009077485; 2009
72. Auspex Pharmaceuticals, Inc. Preparation
of deuterated oxazolidinones with
improved metabolic, pharmacodynamic,
and toxicity properties for treatment of
muscle skeletal disorders.
WO2009132119; 2009
73. Pharmacia & Upjohn Company LLC.
Substituted 2,3,5-trifluorophenyl
oxazolidinones for use as antibacterial
agents. WO2005113520; 2005
74. Astrazeneca AB. Preparation of
3-[4-(pyridin-3-yl)phenyl]-5-(1H-1,2,3-
triazol-1-ylmethyl)oxazolidin-2-ones as
antibacterial agents.
WO2005116022; 2005
75. Dostert P, Strolin-Benedetti M,
Guffroy C. Different stereoselective
inhibition of monoamine oxidase-B
by the R- and S-enantiomers of
MD 780236. J Pharm Pharmacol
1983;35:161-5
76. Gates KS, Silverman RB.
Model studies for the mechanism of
inactivation of monoamine oxidase by
5-aminomethyl-3-aryl-2-oxazolidinones.
J Am Chem Soc
1989;111:8891-95
and reference therein
77. Hauck SI, Cederberg C, Doucette A,
et al. New carbon-linked azole
oxazolidinones with improved potency
and pharmacokinetics. Bioorg Med
Chem Lett 2007;17:337-40
78. Park C-H, Brittelli DR, Wang CL-J,
et al. Antibacterials. Synthesis and
structure-activity studies of
3-aryl-toxooxazolidines. 4.
Multiply-substituted aryl derivatives.
J Med Chem 1992;35:1156-65
79. Flaherty P, Castagnoli K, Wang Y-X,
Castagnoli Jr N. Synthesis and
selective monoamine oxidase
B-inhibiting properties of 1-methyl-
1,2,3,6-tetrahydropyrid-4-yl carbamate
derivatives: potential prodrugs of
(R)- and (S)-nordeprenyl. J Med Chem
1996;29:4756-61
80. Tan AK, Weyler W, Salach JI,
Singer TP. Differences in substrate
specificities of monoamine oxidase
A from human liver and placenta.
Biochem Biophys Res Commun
1991;181:1084-8
81. Toth PP, Urtis J. Commonly used
muscle relaxant therapies for acute low
back pain: a review of carisoprodol,
cyclobenzaprine hydrochloride, and
metaxalone. Clin Ther
2004;26(9):1355-67
82. Weyler W, Salach JI. Purification and
properties of mitochondrial monoamine
oxidase type A from human placenta.
J Biol Chem 1985;260:13199-207
83. Uebelhack R, Franke L, Schewe HJ.
Inhibition of platelet MAO-B by kava
pyrone-enriched extract from Piper
methysticum Forster (kava-kava).
Pharmacopsychiatry
1998;31(5):187-92
84. Auspex Pharmaceuticals, Inc. Preparation
and utility of deutero-substituted
amphetamines useful in the treatment of
trauma, post-traumatic-stress-disorder
and psychological disorders.
WO2008016677; 2008
85. Auspex Pharmaceuticals, Inc.
Deuterium-substituted tadalafil as
PDE-5 inhibitors and their preparation
and use in the treatment of
PDE-5-mediated diseases.
WO2007146124; 2007
86. Universitaet Tuebingen. Preparation of
fluoroamphetamines as antiparkinsonian
agents. WO2008113565; 2008
87. Schmidt WJ, Mayerhofer A, Meyer K,
Kovar K. Ecstasy counteracts catalepsy
in rats, an anti-parkinsonian effect?
Neuroscience Lett 2002;330:251-4
88. Kirton & Mcconkie. Methods and
compositions for inhibiting monoamine
oxidase and catechol-O-methyltransferase.
US2005202109; 2005
89. Rojas Castaneda P. Novel use of Gingko
biloba extract for treating Parkinson’s
disease. WO2006004386; 2006
90. Vitaplant AG. Tannin-free extract of
Rhodiola rosea. WO2008009151; 2008
91. Hong Kong Jockey Club Institute of
Chinese Medicine Ltd. Antidepressant
formulations comprising the extracts of
Psoralea corylifolia and Poria cocos.
US2006147569; 2006
92. Kong LD, Tan RX, Woo AY,
Cheng CH. Inhibition of rat brain
monoamine oxidase activities by psoralen
and isopsoralen: implications for the
treatment of affective disorders.
Pharmacol Toxicol 2001;88(2):75-80
93. Schurr A, Livne A. Different inhibition
of mitochondrial monoamine oxidase
from brain by hashish components.
Biochem Pharmacol 1976;25:1201-3
94. Yu ZF, Kong LD, Chen Y.
Antidepressant activity of aqueous
extracts of Curcuma longa.
J Ethnopharmacol 2002;83:161-5
95. Steru L, Chermat R, Thierry B,
Simon P. The tail suspension test: a new
method for screening antidepressants in
mice. Psychopharmacology
1985;85:367-70
96. Willner P. Validity, reliability and
utility of the chronic mild stress model
of depression: a 10-year review and
evaluation. Psychopharmacology
1997;134:319-29
97. Huazhong Agricultural University,
Peop. Rep. China. New formulations of
Lotus proanthocyanidins for treating
Alzheimer’s disease. CN1943570; 2007
98. Oxford Pharmaceutical Services, Inc.
Methods and pharmaceutical
compositions using monoamine oxidase
inhibitors for treating or preventing
migraines. WO2007038675; 2007
99. Zogenix, Inc. Novel formulations for
treatment of migraine.
WO2009134336; 2009
100. Alcon Manufacturing, Ltd. Monoamine
oxidase inhibitors useful for treating
disorders of the outer retina.
WO2008014457; 2009
101. Takahata K, Katsuki H, Kobayashi Y,
et al. Protective effects of selegiline and
desmethylselegiline against
N-methyl-D-aspartate-induced rat
Bolasco, Carradori & Fioravanti
Expert Opin. Ther. Patents (2010) 20(7) 937
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
retinal damage. Eur J Pharmacol
2003;458(1-2):81-9
102. Buys YM, Trope GE, Tatton WG.
(-)-Deprenyl increases the survival of rat
retinal ganglion cells after optic nerve
crush. Curr Eye Res 1995;14(2):119-26
103. Reme C, Aeberhard B, Schoch M.
Circadian rhythm of autophagy and light
responses of autophagy, and
disk-shedding in the rat retina.
Trans Ophthalmol Soc UK
1983;103:405-10
104. Abler AS, Chang CJ, Fu J, et al.
Photoic injury triggers apoptosis
of photoreceptor cells.
Res Commun Mol Path Pharmacol
1996;92:177-89
105. Overfield WD. Methods for preventing
or treating bruxism using dopaminergic
agents. US2009247537; 2009
106. Teva Pharmaceutical Industries, Ltd.
Use of rasagiline for the treatment of
multiple system atrophy.
WO2007098264; 2007
107. Wenning GK. Multiple System Atrophy.
Lancet Neurol 2004;3(2):93-103
108. Cooper & Dunham, LLP. Method for
the treatment of glaucoma using
rasagiline. US2009062400; 2009
109. Farkas RH, Grosskreutz CL. Apoptosis,
neuroprotection and retinal ganglion cell
death: an overview. Int Opthalmol Clin
2001;41:111-30
110. Somerset Pharmaceuticals, Inc.
Desmethylselegiline for treatment of
cerebrovascular disease.
WO2007117286; 2007
111. Knollema S, Aukema W, Hom H, et al.
L-Deprenyl reduces brain damage in rats
exposed to transient hypoxia-ischemia.
Stroke 1995;26(10):1883-7
112. Teva Pharmaceutical Industries, Ltd. Use
of ladostigil for the treatment of multiple
sclerosis. WO2006130726; 2006
113. University of Padua. Treatment of heart
failure and associated conditions by
administration of monoamine oxidase
inhibitors. US2009286883; 2009
114. Bianchi P, Kunduzova O, Masini E,
et al. Oxidative stress by monoamine
oxidase mediates receptor-independent
cardiomyocyte apoptosis by serotonin
and post-ischemic myocardial injury.
Circulation 2005;112:3297-305
115. Youdim MBH, Weinstock M.
Therapeutic applications of selective and
non-selective inhibitors of monoamine
oxidase A and B that do not cause
significant tyramine potentiation.
Neurotoxicology 2004;25(1-2):243-50
116. Jenrin Discovery. Preparation of
N-benzyl-N-propargyl-amines as MAO
inhibitors for treatment of obesity.
WO2008092091; 2008
117. Jenrin Discovery. MAO-B inhibitors
useful for treating obesity.
WO2007008963; 2007
118. Jenrin Discovery. MAO-B inhibitors
useful for treating obesity.
WO2006138475; 2006
119. McElroy JF, Chorvat RJ. MAO-B
inhibitors useful for treating obesity.
WO2006130707; 2006
120. L’Oreal, Fr. Use of inhibitors of
monoamine oxidase for capillary
pigmentation. FR2928545; 2009
121. Chu CY, Liu YL, Chiu HC, Jee SH.
Dopamine-induced apoptosis in human
melanocytes involves generation of
reactive oxygen species. Br J Dermatol
2006;154:1071-9
122. Cutech S.r.l. Compositions comprising
MAO inhibitors for treatment of
disorders of hair follicles.
EP2033687; 2009
123. Lines TC. Composition comprising
inhibitors of serotonin, monoamine
oxidase, and phosphodiesterase for
treating mental health disorders.
WO2006091988; 2006
124. Chelsea Therapeutics, Inc.
Pharmaceutical compositions comprising
combinations of droxidopa with
catechol-O-methyltransferase inhibitors,
cholinesterase inhibitors, or
monoamine-oxidase inhibitors, for
treating conditions such as orthostatic
hypotension. WO2008003028; 2008
125. Chelsea Therapeutics, Inc. Droxidopa
and pharmaceutical composition thereof
for the treatment of mood disorders,
sleep disorders, or attention deficit
disorders. WO2008137923; 2008
126. Goldstein DS. L-Dihydroxyphenylserine
(L-DOPS): a norepinephrine prodrug.
Cardiovas Drug Rev
2006;24(3-4):189-203
127. Fabre-Kramer Pharmaceuticals, Inc.
Indolylalkyl derivatives of
pyrimidinylpiperazine and metabolites
thereof for treatment of anxiety,
depression, and sexual dysfunction.
WO2009137733; 2009
128. Ellneuroxx, Ltd. Synthesis of
dihydroxyphenylalanine derivatives for
use in treatment of brain disorders.
WO2006119758; 2006
129. Janssen Pharmaceutica, N.V.
Phenylalaninol carbamate compound
adjunctive therapy for depression.
WO2006050037; 2006
130. Doody RS, Gavrilova SI, Sano M, et al.
Effect of dimebon on cognition,
activities of daily living, behaviour,
and global function in patients with
mild-to-moderate Alzheimer’s disease:
a randomised, double-blind,
placebo-controlled study. Lancet
2008;372:207-15
131. Medivation, Inc. Methods and
combination therapies for treating
Alzheimer’s disease.
WO2008051599; 2008
132. Cypress Biosciences, Inc. Improving the
tolerability of a serotonin antagonist and
a NSRI (norepinephrine serotonin
reuptake inhibitors), a SNRI (serotonin
norepinephrine reuptake inhibitors) or a
RIMA (reversible inhibitors of
monoamine oxidase A) by using them in
combination. WO2009023820; 2009
133. The University of Montana, USA.
Method using a central nervous system
stimulant, monoamine neurotransmitter,
monoamine oxidase inhibitor, or tricyclic
antidepressant for reducing neuronal cell
damage caused by transient cerebral
hypoxia and/or ischemia.
WO2008024660; 2007
134. Janssen Pharmaceutica, N.V.
Treatment of sexual dysfunction with
amino(phenyl)alkyl carbamates.
WO2007001841; 2007
135. Foreman MM. Disorders of sexual
response: pioneering new pharmaceutical
and therapeutic opportunities. Exp Opin
Invest Drugs 1995;4:621-36
136. Richter Gedeon Vegyeszeti Gyar Rt.
Pharmaceutical combinations of
voltage-gated sodium channel blockers
and monoamine oxidase B inhibitors.
WO2007060491; 2007
137. Clare JJ, Tate SN, Nobbs M,
Romanos MA. Voltage-gated sodium
channels as therapeutic targets.
Drug Discov Today 2000;5:506-20
138. Chongqing Pharmaceutical Research
Institute Co., Ltd. Transdermal patch
containing rasagiline for treatment or
prophylaxis of nervous system disease
Focusing on new monoamine oxidase inhibitors
938 Expert Opin. Ther. Patents (2010) 20(7)
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
and its preparation process.
WO2007101400; 2007
139. Newron Pharmaceuticals S.p.A.
Process for the production of highly
pure 2-[4-(3- or 2-fluorobenzyloxy)
benzylamino]propanamides as
cytochrome P450 inhibitors and their
pharmaceutical compositions and use
in the treatment of diseases.
WO2009074478; 2009
140. Pevarello P, Bonsignori A, Dostert P.
Synthesis and anticonvulsant activity of a
new class of 2-[(arylalkyl)amino]alkanide
derivatives. J Med Chem 1998;41:579-90
141. Anup K, Upadhyay, Jin Wang, Dale E.
Edmondson comparison of the
structural properties of the active site
cavities of human and rat monoamine
oxidase A and B in their soluble and
membrane-bound forms. Biochemistry
2008;47:526-36
142. Novaroli L, Daina A, Favre E, et al.
Impact of species-dependent differences
on screening, design, and development of
MAO B inhibitors. J Med Chem
2006;49:6264-72
AffiliationAdriana Bolasco†1, Simone Carradori2 &
Rossella Fioravanti2
†Author for correspondence1Professor,
Dipartimento di Chimica e
Tecnologie del Farmaco,
Universita degli Studi di
Roma “La Sapienza”,
P.le Aldo Moro,
5 00185 Rome, Italy
Tel: +39 6 49913923;
E-mail: [email protected] di Chimica e
Tecnologie del Farmaco,
Universita degli Studi di
Roma “La Sapienza”,
P.le Aldo Moro,
5 00185 Rome, Italy
Bolasco, Carradori & Fioravanti
Expert Opin. Ther. Patents (2010) 20(7) 939
Exp
ert O
pin.
The
r. P
aten
ts D
ownl
oade
d fr
om in
form
ahea
lthca
re.c
om b
y N
ovar
tis P
harm
a (A
ctiv
e) o
n 07
/02/
10Fo
r pe
rson
al u
se o
nly.
Top Related